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Abstract 
Plasmid DNA offers a novel mechanism to deliver antigens in vivo. Both humoral and 
cellular responses are induced in the systemic and mucosal compartments following 
mucosal administration. These properties suggest plasmid DNA represents a very 
promising technology for future vaccine development. However, the major disadvantage 
of this method of vaccination currently is the requirement for large doses of plasmid 
DNA needed to be efficacious in man. Therefore, by elucidating the mechanism 
underlying cellular transfection and improving the immunogenicity of plasmid DNA 
vaccines, the amount of plasmid DNA required to induce a protective immune response 
may be reduced. To further this goal, this study has investigated the use of cytofectins 
and translocation peptides to improve the efficiency of plasmid DNA delivery, and to 
enhance the immune response by co-delivery of genetic adjuvants. 
The optimal parameters to complex cytofectins with plasmid DNA were compared in 
their efficiency to transfect cells in vitro. The efficiency of cytofectin complexed plasmid 
DNA delivery was also investigated in vivo, by administering plasmid DNA cytofectin 
complexes by the intranasal route. Dendritic cells containing the transgene were observed 
at the site of administration and at the draining lymph node. 
This study also investigated a novel delivery system for plasmid DNA delivery. We have 
investigated the properties of the homeoprotein Antennapedia in complexing plasmid 
DNA and demonstrated enhanced transfection compared to naked plasmid DNA in vitro. 
Finally, this study investigated the chemokine CCL20 to act as a molecular adjuvant. 
CCL20 was cloned into an expression vector and after intranasal or intradermal delivery 
can increase the number of dendritic cells recruited to the site of administration. 
In summary, this study has demonstrated that the efficacy of plasmid DNA can be 
improved through optimising delivery and that by using molecular adjuvant, CCL20, the 
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1.1 Vaccination 
In 1796 Edward Jenner demonstrated that using liquid from cow pox sores, he could 
protect against small pox infection. Thus coining the term "vaccination" from the latin 
word for cowpox, vaccinia. However, it was in 1880 when Louis Pasteur further 
contributed to the study of vaccines when he reported to the French Academy of Science 
that 4' ... chicken cholera is produced by a microscopic parasite, that there exists an 
attenuated virus of that disease, and that one or more inoculations of this attenuated virus 
can preserve the animals from the moral effects of a later inoculation.... ". 
As a result of whole spread vaccination, endemic childhood infectious diseases have 
virtually disappeared from industrialised countries. These are remarkable successes, 
which together with clean water and antibiotics have profoundly affected human society 
(Bland and Clements 1998). However, there are still many infectious diseases that do not 
currently have a working vaccine, for example Malaria. Therefore, we need to utilise 
modem scientific knowledge to design efficacious vaccines. 
1.1.1 Designing Vaccines 
Several factors must be kept in mind in developing a successful vaccine. First and 
foremost, the development of an immune response does not necessarily mean that a state 
of immunity has been achieved. Often the quality of the immune response 
is critical, for 
example biasing a response towards the Thl pathway, may 
be protective for some 
organisms, but in others could exacerbate the disease. A second 
factor is the development 
16 
of immunological memory. For example a vaccine that induces a protective primary 
response may fail to induce memory-cell formation, leaving the host unprotected after the 
primary response to the vaccine subsides. This increases the number of vaccinations 
required, reducing patient compliance and the proportion of the herd protected. 
1.1.2 Classic methods of Vaccine Development 
Since the time of Pasteur until recently there have been 2 mains paths of vaccine 
development: attenuation and inactivation. Attenuated vaccines are organisms that have 
are viable but are non-pathogenic. Whereas, inactivated vaccines are either parts of 
organisms (subunit vaccines) or organisms that have been killed (Inactivated vaccines). 
1.1.2.1 Attenuation 
The first attenuated vaccines were created by Pasteur for rabies and anthrax. This was 
accomplished through barraging the organism using heat, oxygenation, chemical agents 
or aging. Passage in animal hosts, such as embryonated hen's egg was practiced by 
Theiler for a yellow fever vaccine, and then with the development of cell culture in the 
1940's, attenuation in vitro was accomplished by a variety of means including selection 
of chance mutants, adaptation to growth at low temperatures, chemical mutation to 
induce inability to grow at high temperature (temperature sensitivity), or induction of 
auxotrophy in bacteria. 
17 
1.1.2.1a Poliomyelitis 
An example of a successful vaccine is the polio vaccine, with the wild polioviruses being 
limited to only 2 parts of the world - sub-Saharan Africa and the Indian subcontinent. 
However, the virus will never be totally eradicated as the vaccine itself acts a repository. 
Although the attenuated poliovirus strains were passaged more than 70 times in animals 
or cell culture, the property of attenuation rests on a small number of mutations (Martin 
and Minor 2002). Those mutations change only I% of amino acids, and most of the 
changes have nothing to do with attenuation. Moreover, after oral administration to 
humans, reversion of the few attenuating mutations is a constant feature of replication in 
the intestine, where neurovirulent viruses have a selective advantage. 
The other facet of the problem is that recombination between poliovirus serotypes and 
between poliovirus and enteroviruses is a regular phenomenon during replication in the 
intestine. When the 5' end of a reverted poliovirus combines with the 3' end of another 
enterovirus, the result is a virus that not only is neurovirulent but also can be transmitted 
easily and become epidemic (Kew et aL 2002). Epidemic vaccine-derived polio has 
happened in the past in Egypt, China, Israel, the Dominican Republic, Haiti, the 
Philippines and Madagascar, undoubtedly accompanied by hundreds of asymptomatic 
infections. In addition, rarely persons with B cell deficiencies chronically excrete 
reverted vaccine virus, for periods of greater than 10 years (Kew et al. 1998; Cherkasova 
et al. 2002). 
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1.1.2.2 Inactivated organism or subunit 
Late in the 19'h century, Theobald Smith in the United States and Pasteur's colleagues 
independently showed that whole organisms could be killed without losing 
immunogenicity, which soon became the basis of vaccines for typhoid and cholera and 
later for pertussis, influenza and hepatitis A. In the 1920s, the exotoxins of 
Corynebacterium di htheriae and Clostridium tetani were inactivated by formalin to 
provide antigens for immunisation against diphtheria and tetanus. Later in the 20th 
century influenza vaccine progressed to subunit preparations, and pertussis vaccine 
progressed from bacterial soup to the extracted proteins that we use today in acellular 
vaccines. Extracted native polysaccharides from the capsules of Haemophilus influenzae 
type b, pneurnococci, meningococci, and typhoid bacilli proved useftil in immunising 
older children and adults, and more recently, the conjugation of these polysaccharides 
with proteins have provided us with immunogens that generate T cell memory and are 
effective even in young infants. 
Although these vaccine strategies have been successful, they have not been able to 
address some of the most deadly diseases. Effective vaccines are still required for HIV, 
Tuberculosis, and Malaria. Novel strategies to induce an immune response and act as a 
vaccine vector have been investigated. These include the potential to use plasmid 
DNA 
to induce an immune response against an encoded antigen. 
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1.1.3 Vaccine Strategies 
1.1.3.1 Recombinant Vector Vaccines 
It is possible to introduce genes encoding major antigens of especially virulent pathogens 
into attenuated viruses or bacteria. The attenuated organism serves as a vector, replicating 
within the host and expressing the gene product of the pathogen. A number of organisms 
have been investigated as potential vector vaccines, including vaccinia virus, the 
canarypox virus, attenuated poliovirus, adenoviruses, attenuated strains of Salmonella, 
and the BCG strain of Mycobacterium bovis. 
The viral vectors recently in laboratory and clinical use are based on RNA and DNA 
viruses possessing very different genomic structures and host ranges. Particular viruses 
have been selected as gene delivery vehicles because of their capacities to carry foreign 
genes and their ability to efficiently deliver these genes associated with efficient gene 
expression. These are the major reasons why viral vectors derived from retroviruses, 
adenovirus, adeno-associated virus, herpesvirus and poxvirus are employed in more than 
70% of clinical gene therapy trials worldwide. Among these vector systems, retrovirus 
vectors represent the most prominent delivery system, since these vectors have high gene 
transfer efficiency and mediate high expression of gene products. Members of the DNA 
virus family such as adenovirus-, adeno-associated virus or 
herpesvirus have also become 
attractive for efficient gene delivery as reflected 
by the fast growing number of clinical 
trials using these vectors. The first clinical trials were 
designed to test the feasibility and 
safety of viral vectors. Numerous viral vector systems 
have been developed for ex vivo 
and in vivo applications. More recently, 
increasing efforts have been made to improve 
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infectivity, viral targeting, cell type specific expression and the duration of expression. 
These features are essential for higher efficacy and safety of RNA- and DNA-virus 
vectors. From the initial investigations that utilised viral vectors it was apparent that they 
harbour risks such as toxicities, immunoresponses towards viral antigens or potential 
viral recombination that limited their clinical use. However, many achievements have 
been made in vector safety, the retargeting of virus vectors and improving the expression 
properties by refining vector design and virus production. 
One potential of recombinant viral vectors that has been successful in the literature is a 
prime boost strategy. Priming is accomplished with a plasmid DNA encoding the antigen 
of choice, and is followed by boosting with a viral vector (Pinto et al. 2003). Thereby 
increasing the magnitude and duration of the response as compared to boosting with 
plasmid DNA alone. Studies have demonstrated that previous immunological exposure to 
modified Vaccinia-Ankara virus (MVA) reduced the efficiency of subsequent priming 
and boosting using the same vaccine vehicle. However, a combined regime whereby the 
animals were first primed with the DNA vaccine and then boosted with MVA was the 
most potent protocol for the induction of both interferon-gamma-producing and cytolytic 
T cells against two CTL epitopes simultaneously (Hanke et al. 1998). 
1.1.3.2 Synthetic Peptide accines 
Among the synthetic peptide vaccines currently being evaluated are those for hepatitis B 
virus, the malaria parasite, diphtheria toxin, influenza and 
HIV. Construction of synthetic 
peptides for use as vaccines to induce either 
humoral or cell-mediated immunity requires 
knowledge of the T-cell and B-cell epitopes of the antigen. 
In the design of synthetic 
21 
peptides, the primary structure of the antigen is analysed to identify strongly hydrophilic 
sequences, which most likely correspond to B-cell epitopes. Ideally immunodominant 13- 
cell epitopes are identified for use as a synthetic peptide vaccine. However, a successful 
vaccine also requires a cell-mediated immune response; therefore immunodominant T 
helper cell epitopes are required. These peptides must have a site (the agretope) that 
enables them to interact with the NMC molecules as well as a site (the epitope) that 
enables them to interact with the T cell receptor. Since MHC molecules differ in their 
ability to present peptides to T cells, MHC polymorphism within a species influences the 
level of T-cell responsiveness by different individuals to different peptides. 
1.1.3.4 Multivalent Subunit Vaccines 
The limitation with synthetic peptide vaccines and recombinant protein vaccines is that 
these vaccines tend to be poorly immunogenic; in addition, they tend to induce a humoral 
antibody response but are less likely to induce a cell-mediated response. Therefore, a 
vaccine needs to contain both immunodominant B and T cell epitopes. If a CTL response 
is desired the vaccine must be delivered intracellularly so that the peptides can be 
processed and presented together with class I MHC molecules. 
One approach is to Prepare solid matrix-antibody-antigen (SMAA) complexes by 
attaching monoclonal antibodies to particulate solid matrices and then saturating the 
antibody with the desired antigen. By attaching different monoclonal antibodies to the 
solid matrix, it is possible to bind a mixture of peptides or proteins, composing 
immunodominant epitopes for both T cells and B cells, to the solid matrix (Alber et al. 
2000). These multivalent complexes have been shown to induce vigorous humoral and 
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cell-mediated responses. Their particulate nature contributes to their increased 
immunogenicity by facilitating phagocytosis. 
1.1.3.5 Anti-ldiotype vaccines 
Monoclonal anti-idiotypic antibodies (ab2 MAbs), which bear internal images of 
neutralization epitopes of viruses, are potentially useful as antiviral vaccines. Such ab2, 
MAbs evoke virus neutralizing anti -anti -idiotypic (ab3) antibodies that might protect 
immunized animals against virulent viral disease. Anti-idiotype vaccines have been 
shown to induce protective immunity in mice against hepatitis B virus and several other 
pathogens (Zanetti et aL 1987). The development of an anti-idiotype vaccine for humans 
hold much promise when immunisation with a killed or attenuated vaccine would pose an 
unacceptable risk. 
1.2 DNA Vaccines 
1.2.1 Historical background. 
In 1960 the first use of a naked DNA was documented by Ito, who demonstrated the 
induction of papillomas in rabbit skin by injection of purified nucleic acid extracted from 
the Shope rabbit papilloma virus. However, it was not until 1990 that the true potential of 
this method of vaccination was visualised. Wolff et al reported that 
intramuscular 
injection of plasmid DNA in a simple saline solution could transfect muscle cells 
in vivo 
and persist in an episomal form, thus potentially able to 
induce an immune response 
against the expressed proteins. In 1992, Tang et al were the 
first to show the induction of 
antigen specific antibodies resulting from plasmid 
DNA injection via a "gene gun" into 
mice However it was in 1993, when Ulmer et al 
demonstrated that mice could be 
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protected from influenza virus challenge by the induction of antibody and CD8 cýiotoxic 
T lymphocytes (CTL) responses when previously immunised with a DNA vaccine, that 
the true potential of this method of vaccination came to fruition. Since then, the 
immunogenicity or protective efficacy of DNA vaccines in preclinical models of 
infectious disease, allergy and cancer has been established in several animal species and 
attests to the simplicity and robustness of the technology. 
1.2.2 Basic elements of a plasmid vector 
1.2.2.1 Description of the plasmid vector 
The basic elements of a bacterial vector used as a DNA vaccine are: a promoter and 
enhancer (to enable transcription of the inserted foreign gene); an mRNA transcription 
termination/polyadenylation signal (for directing expression in mammalian cells); an 
antibiotic resistance gene (to confer an antibiotic selectable marker for growth in E. Coli. ); 
an origin of replication for growth in E. Coli; and specific nucleotide sequences, cytidine- 
phosphate-guanosine (referred to as CpG motifs) which are stimulatory for lymphocytes 
and act as an adjuvant. 
1.2.2.2 Promoter/enhancer region within a plasmid vector 
There are 2 main features within the bacterial plasmid DNA vector that are essential 
for 
optimal expression within mammalian cells. These are a strong promoter/enhancer and 
the transcriptiOn/termination sequence. The majority of DNA vaccines contain either the 
human cytornegalovirus (CMV) immediate/early (IE) promoter (Boshart et al. 
1985). the 
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SV40 early promoter (Moreau et aL 1981) or the Rous Sarcoma virus LTR (Gorman et 
al. 1982). In conjunction with one of these promoters. a polyadenylation sequence from 
either bovine growth hormone (BGH) or SV40 is required to stabilise the mRNA (Pfarr et 
al. 1986). A caveat to the use of these promoters are the reports that interferon-y (IFN-y) 
is released in situ during the priming of an immune response (as a result of the 
inflammatory cytokine inducing properties of bacterial DNA), thus suppressing 
transcription from many viral promoters (Harms and Splitter 1995; Romero and Lavine 
1996). This in turn can affect the magnitude of the immune response. by limiting antigen 
production for B and T cell priming. There have been studies using alternatives to virus 
derived control elements for example promoter/enhancer sequence driving expression of 
NMC class I and 11 (Xiang et al. 1997; Gebhard et al. 2000), dectin in Langerhan' cells 
(Bonkobara et al. 2001) and muscle specific genes (Bamhart et al. 1998; Kwissa et al. 
2000) have all been investigated, however the levels of expression do not exceed those 
generated from the HCMV IE promoter combined with the CMV intron A. Further 
optimisation of expression has been reported by the inclusion of a 'Kozak' translational 
initiation sequence 5' to the start codon of the inserted 'foreign' gene. 
1.2.3 Cellular interaction of plasmid DNA 
The precise mechanism by which naked plasmid DNA enters cells and is translocated to 
the nucleus to initiate transcription is not fully understood. 
Evidence from electron 
micrographs suggests plasmid DNA is internalised 
by electrostatic binding to the cell 
membrane and endocytosed via clathrin coated pits 
(Zabner et al. 1995, Friend et al. 
1996). Direct fusion with the cell membrane and/or fluid phase endocýtosis 
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(macropinocytosis) (Apodaca 2001) may also contribute to cellular uptake of plasmid 
DNA. Once plasmid DNA is internalised, rapid escape from the endosome is critical to 
the efficiency of plasmid encoded antigen expression. Endosomes mature through various 
stages of acidification and eventually fuse with lysosomes containing enzymes, x, ý-hich 
degrade DNA. Release of plasmid DNA from the endo-lysosome is thought to be a 
consequence of membrane disruption. Cationic lipids or peptides (eg from the 
haernagglutinin of influenza virus) which fuse with the endosomal membrane have been 
reported to increase transfection efficiency (Fasbender et al. 1997; Zhang et al. 2001). 
Despite these modifications only a fraction of intemalised plasmid DNA penetrates the 
cytoplasm. Plasmid DNA is prone to further degradation by cytosolic nucleases, thus 
only a very small proportion of transfected DNA is available for transport across the 
nuclear membrane (Johnson-Saliba and Jans 2001). The size of plasmid DNA vectors is 
generally assumed to preclude efficient diffusion across the nuclear pore complex, thus 
compounding the inefficiency of plasmid DNA transfection. Following transcription, 
mRNA is translated and plasmid-encoded protein within the cytoplasm is accessible to 
the TAP dependant MHC class I processing pathway. 
1.2.4 Generation of Immune Responses by DNA Vaccines 
1.2.4.1 Processing and presentation of plasmid DNA 
For the presentation of plasmid DNA encoded antigen to B cells, 
it appears that as long 
as antigen is accessible to the B cell receptor, the nature of the 
transfected cell exporting 
the plasmid DNA encoded protein is immaterial 
(Loirat et al. 1999: Armand et al. 2000). 
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For DNA vaccines expressing purely cytosolic proteins it had been suggested that antigen 
release to the extracellular milieu might be affected by the CTL lysis of the transfected 
cell. However, recent data indicated that neither perforin nor CD8+ T cell mediated lysis 
is required for priming CD4+ T cell or antibody responses (Hassett et al. 1999) 
For the priming of CD8+ T cell responses there are at least three mechanisms by which 
plasmid DNA encoded antigen may be processed and presented. These include (i) direct 
transfection and priming by somatic cells (such as myocytes, fibroblasts and 
kerationcytes), (ii) cross priming, whereby antigen is transferred from transfected somatic 
cells to professional APCs or (iii) direct transfection of APCs. 
1.2.4.2 Direct priming 
The observation that intramuscular injection of plasmid DNA induced protein expression 
in muscle (Wolff et aL 1990) and elicited strong CD8+ CTL responses in mice (Ulmer et 
al. 1993) suggested that muscle cells were critically involved in the initiation of CTL 
responses. In support of this, was shown that adoptive transfer of stably transfected 
myoblasts expressing influenza nucleoprotein into mice was sufficient to 
induce CD8+ 
CTL and protect from virus challenge (Ulmer et al. 1996). This showed that antigen 
expression by muscle cells was sufficient to prime 
for CTL-mediated protection. 
Unresolved was whether CTL responses were directly induced 
by myocytes expressing 
the encoded antigen or were indirectly induced through antigen 
transfer from myocý-tes to 
professional APCs. To resolve this 
issue, a study examining somatic versus bone marrow 
derived APC CTL priming was undertaken. Bone-marrow 
derived cells were adopti,,, elý 
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transferred to irradiated FI hybrid mice, to create bone marrow chimeras with somatic 
cells of both Fl MHC haplotypes and APCs of a single MHC haplotype of the donor 
bone marrow. Peptide-specific CTL were only induced by immunisation of mice with 
plasmid DNA encoding the peptide presented by the MHC class I molecules found on the 
donor bone marrow (Fu et al. 1997; Iwasaki et al. 1997). These studies demonstrated that 
bone marrow derived APC play a dominant role in CTL priming and suggested that either 
APCs were directly transfected or that antigens (or their epitopes) synthesized in somatic 
cells could be transferred to APCs for presentation by MHC class I molecules. 
1.2.4.3 Cross-priming by DNA vaccines. 
Cross-presentation of antigenic material from apoptotic cells to DCs has been established 
as an important mechanism for the induction of CD8+ CTL responses against tumour or 
pathogen derived antigens (Bevan 1976). In vitro studies have established that this 
mechanism is distinct from the classical endogenous TAP dependent pathway of MHC 
class I restricted peptide presentation. Several lines of evidence indicate that cross- 
priming also occurs following DNA vaccination. Loriat et al, 1999, have shown that 
vaccination with a plasmid DNA vector driven by a muscle specific promoter elicited 
CTL despite expression of antigen restricted to muscle cells, suggesting that cross 
presentation of antigen to APC was involved. Second, Corr et al, 1999, demonstrated 
using a transactivating plasmid system and bone marrow chimeras that CTL 
induction by 
plasmid DNA was critically dependant upon antigen expression 
by somatic cells and 
transfer to APCs. However, a complementary mechanism involving direct transfection of 
APCs could not be excluded. More recently, cross-presentation of antigen to 
DCs has 
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been facilitated by constructing DNA vaccines that induce apoptotic death of the antigen- 
expressing cell. Co-immunisation with DNA vaccines which express Fas or a mutated 
version of a caspase gene which induce the creation of apoptotic bodies has been reported 
to enhance cell mediated immunity (Chattergoon et al. 2000; Sasaki et al. 200 1). The 
underlying mechanism by which antigen is transferred from somatic cells to APCs is not 
fully understood. Chaperones, including heat shock protein 70 and 73 (hsp70, hsp73) 
have been implicated in the transfer of immunogenic material from plasmid DNA 
transfected macrophages or somatic cells to DCs (Kumaraguru et aL 2000; Kammerer et 
al. 2002). The precise mechanism by which chaperone-bound peptides are released and 
cross-presented by DC's remains to be resolved. Candidate mechanisms include either a 
facilitated exchange or delivery system, whereby chaperone-bound peptide is intemalised 
following receptor mediated DC binding with peptide exchange between nascent MHC 
class I molecules and the chaperone. Alternatively chaperone-bound peptide may be 
directly exchanged with cell surface MUC class I bound peptide. 
1.2.4.4 Direct transfection of antigen presenting cells 
While there is evidence for cross-priming, other studies have provided evidence that 
APCs are directly transfected following DNA vaccination. Removal of muscle (within 10 
minutes) from the injection site of a DNA vaccine did not alter the magnitude or quality 
of the subsequent immune response, suggesting transfection of cells 
(possibly APCs) 
distal to the injection site is sufficient to prime CTL (Torres et al. 1997). Antigen and 
reporter genes have been demonstrated in macrophages, 
Langerhan' cells and I)Cs 
present both at the site of DNA vaccine delivery and 
in draining lymph nodes 
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(Chattergoon et al. 1998; Akbari et al. 1999; Barnfield et al. 2000). This suggests that 
APCs are transfected in situ and migrate to draining lymph nodes or altemativelY are 
transfected within lymph nodes following lymphatic drainage of plasmid DNA. 
Conclusively, plasmid encoded mRNA has been demonstrated in isolated DCs folloNN ing) 
either intradermal or mucosal vaccine delivery (Bouloc et al. 1999; Barnfield et al. 2000). 
Functional studies have demonstrated that DCs isolated from plasmid DNA injected skin 
or nasal tissue were able to stimulate the proliferation of T cell responses in na*fve mice 
following adoptive transfer (Bouloc et al. 1999). These reports indicate that different 
routes of DNA vaccine delivery result in direct transfection of APCs and lead to 
induction of CTL responses. Current evidence suggests the efficiency of DC transfections 
in vivo is very low (Barnfield et al. 2000). However, considering the potent stimulatory 
activity of DCs (Steinman and Pope 2002), large numbers of transfected DC may not 
actually be essential to elicit CTL responses. In support of this hypothesis, adoptive 
transfer of as few as 500-1000 in vitro transfected DCs to mice induced a comparable 
cellular and humoral immune response as that elicited by gene gun immunisation with the 
same antigen encoding plasmid (Timares et al. 1998). 
1.2.5 Augmenting the Immunogenicity of DNA Vaccines 
Pre-clinical studies, in several murine models of infectious disease have shown that DNA 
vaccines effectively elicit cellular and humoral immune responses, which confer 
protection from pathogen challenge (Ulmer et al. 1993; Gebhard et al. 2000). Whilst 
these observations have been very encouraging, the magnitude of the immune responses 
induced in human and non-human primates by the first generation of naked DNA 
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vaccines has proven lower than that achieved by attenuated or protein adjuvanted 
vaccines (MacGregor et al. 1998; Amara et al. 200 1). This difference in efficacy of DNA 
vaccines between species is in part due to the higher level of protein expression achieved 
in mice following intramuscular injection than in other species (Jiao et al. 1992). 
Secondly, the dose of plasmid DNA injected in mice per Kg body weight, significantly 
exceeds the Per Kg dose administered to human and non-human primates, thus 
comparisons of immunogenicity are not equal. Furthermore, murine cells reportedly 
demonstrate greater sensitivity than human cells to the adjuvant activity of CpG DNA 
(Bauer et al. 2001). Thus while naked DNA vaccines on their own may not be adequate 
to protect against disease in man, technological developments in vector construction, 
incorporation of genetic or conventional adjuvants, deployment of novel delivery 
vehicles or poxvirus booster inoculations may lead to the development of effective DNA 
vaccines. 
1.2.5.1 Modification of the Vector 
It is generally believed that the level of gene expression attained in vivo following DNA 
vaccination correlates with the immune response generated. 
Therefore, approaches to 
improve gene expression may enhance DNA vaccine potency. Virally 
derived promoters, 
including the most frequently used CMV immediate early enhancer-promoter provide 
high levels of gene expression within mammalian cells 
(Manthorpe et al. 1993). 
However, these promoters are subject to transcriptional silencing, 
following CpG DNA 
mediated activation of proinflammatory cytokines 
(Romero and Lavine 1996). 
Elimination of CpG motifs within the plasmid backbone reportedly 
increases the duration 
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of antigen expression (Yew et al. 2001). Whilst this modification may provide the longer 
term expression required for gene replacement therapy, this needs to be balanced with the 
loss of adjuvant activity required for DC maturation and to initiate T cell priming. 
Alternative promoters, including cell-specific, tissue specific and hybrid CMV promoters 
have been evaluated (Xiang et al. 1997; Barnhart et al. 1998; Gebhard et al. 2000; 
Kwissa et al. 2000; Bonkobara et al. 2001). Plasmid vectors containing the human 
ubiquitin promoter could be particularly useful. Sustained, high level gene expression has 
been achieved with this promoter in the presence of plasmid backbones containing CpG 
motifs (Yew et al. 200 1). 
1.2.5.2 Codon optimisation 
Optimising codon usage for eukaryotic cells can also enhance expression of antigens. 
Codon bias has been observed in several species and may differ from the codons most 
frequently used by pathogens. Changes in codon usage, which modify RNA structure, 
have been shown to enhance the expression of HIV env and gag genes. In mammalian 
cells the env and gag genes are made as long unspliced transcripts that contain 
overlapping reading frames with the small regulatory genes of 
HIV rev and tat. These 
transcripts are retained in the nucleus and are rapidly spliced in the absence of rev, thus 
preventing the transport of full-length message to the 
ER. The transcripts are inhibited 
from transport to the ER by rev dependent sequences that are themselves part of the 
structural gene sequence. Structural modification of 
the RNA through changing codon 
usage has led to an increase in HIV envelope and gag expression with an 
increase in HIV 
gp 160 CTL and antibody reported (Vinner et al. 
1999; Andre et al. 2000). 
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1.2.5.4 CpG motifs of plasmid DNA 
Bacterial plasmid DNA contains immunostimulatory sequences (ISS) consisting of 
cytidine-phosphate-guanosine (CpG) dinulceotide sequences, usually flanked by two 5' 
purine and two 3' pyrimidines (Sato et al. 1996). Stimulatory bacterial CpG sequences 
(CpG-S) differ from vertebrate DNA, in that they are unmethylated and expressed at the 
expected frequency (predicted from random base utilisation) whereas this frequency is 
suppressed 20-fold in vertebrate genomes (Bird 1986). These structural differences are 
recognised as "foreign" by vertebrate immune systems and directly activate the innate 
immune system to produce multiple proinflammatory cytokines, including TNF-a, IL-6, 
IL-12ý IL-18 and IFN-oc and IFN-7 (Klinman et al. 1996) which enhance the ability of the 
antigen presenting cells (APQ to present antigen and stimulate T cell activation. When 
the ampR gene was substituted for a kanR selectable marker, which contained additional 
CpG motifs, the modified plasmid was shown to induce an enhanced CTL and IgG 
response compared to the original vector (Sato et aL 1996). However, this ability of CpG 
to stimulate an immune response is abrogated by in vitro methylation (Pasquini et aL 
1999). Co-administration of an empty vector (i. e. without any antigen-coding sequence) 
may boost the immune response to a DNA vaccine; however there appears to be an upper 
limit to the ability of additional CpG motifs to improve the immune response (Krieg et al. 
1998). 
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1.2.5.5 Immunostimulatory effects and mechanisms of CpG 
Recognition of bacterial CpG is mediated by a conserved receptor, Toll like Receptor 9 
(TLR) expressed by macrophages and DC's (Bauer et al. 2001). Current data suggests 
that CpG oligonucleotides cross the cell membrane via sequence non-specific-receptor 
mediated endocytosis and are then recruited to an endosomal compartment where TLR9 
co-localises (Ahmad-Nejad et al. 2002). This is possibly due to CpG release from upon 
plasmid DNA degradation by extracellular nucleases. Endosomal acidification of CpG 
DNA is required to initiate signalling via the Toll/IL-IR pathway, since specific 
inhibitors such as cholorquine block the immunostimulatory activity of CpG DNA 
(Hacker et al. 1998). In macrophages and DCs, CpG-DNA mediated TLR9 signalling is 
transduced by a common adapter protein, myeloid differentiation factor 88 (MYD88) 
which results in the down stream generation of intracellular reactive oxygen species (Yi 
et al. 1998), activation of the mitogen activated kinases (MAPK) and nuclear factor KB 
(NFKB), (Yi and Krieg 1998; Yi and Krieg 1998). The biological outcome of CpG driven 
TLR9 ligation in DC's is secretion of T helper I (Thl) polarising cytokines (IL-12 and 
IL- 18), upregulation of co-stimulatory molecules (CD40, U80 and CD86) and functional 
maturation for antigen presentation (Sparwasser et al. 1998; Schattenberg et al. 2000). 
These observations indicate that the plasmid backbone functions as a Thl polarising 
adjuvant in DNA vaccines and explains the IgG2a antibody and CTL responses seen 
following intramuscular immunisation. CpG also delivers T-independent survival signals 
to DCs that are mediated by up-regulation of the cellular inhibitor of active caspase 
(cIAPs), (Park et aL 2002). This might be a mechanism by which CpG DNA may prolong 
DC presentation of naked DNA encoded antigen and compensate for the relative 
low 
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levels of antigen produced (compared to replicating vectors). The signalling pathways 
activated by CpG DNA in B cells stimulate the secretion of IL-6, IL- 10 and IL- 12 and 
also immunoglobulin in a polyclonal T-independent manner (Krieg et al. 1995). These 
CpG mediated effects synergise with signalling through the B-cell antigen receptor by 
antigen secreted in situ from naked DNA. 
Immune recognition of CpG DNA varies between species, with mouse cells expressing a 
high-responder phenotype and human cells a low-responder phenotype (Bauer et al. 
2001). The CpG motifs optimally active in mice are poor stimulators of innate immunity 
in human PBMC (Bauer et al. 2001). Extensive screening assays have identified 
structurally distinct CpG oligodeoxynucleotide (ODN) sequences, with enhanced 
stimulation for human cells. K-type CpG ODN stimulate IL-6 production by 
monocytes/DCs and B cell proliferation and IgM production. Whereas D-type CpG ODN 
preferentially stimulates IFN-y production by NK cells (Verthelyi et al. 2001). Thus it 
may be possible to improve DNA vaccines for human use by the mutagenesis of 
endogenous plasmid CpG sequences. However, a relative increase in the levels of IFN-7 
induced by CpG-DNA will be compensated by IFN-y mediated suppression of viral 
promoter activity which drives antigen expression. A further level of complexity that 
is 
unravelling is the differential responsiveness of human DC subsets. Human plasmacytoid 
DC (CDI lc+ CD123) are responsive to CpG DNA, but monocyte derived CDI 1+ DC 
lack TLR9 and do not appear to be stimulated (Bauer et al. 2001). Currently this 
difference is difficult to rationalise, in view of the front line defensive location of CD II c+ 
DC at the body surfaces. 
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1.2.6 Genetic Adjuvants for DNA vaccines 
1.2.6.1 Cytokines and Chemokines 
Several groups have used plasmid DNA encoding various cytokine, chemokine or 
co-stimulatory molecules to enhance or polarise the type of immune response generated 
by DNA vaccination. In some instances the outcome attributed to a particular 
immunomodulator has been inconclusive or variable depending upon the antigen, mouse 
strain or plasmid vector used. The variability in response may also reflect the complexity 
of effects attributed to an immunomodulator and those elicited in response to bacterial 
components of the vaccine vector. Co-immunisation with plasmid DNA encoding Th I 
cytokines, IL-12, IL-18, IFN-y, and TNF-(x or chemokines GM-CSF or RANTES with 
antigen coding DNA vaccine constructs has resulted in enhanced CTL and or Th-cell 
proliferative responses. Conversely, co-immunisation with plasmid DNA encoding 
certain Th2 cytokines (eg IL-4, IL-5, IL-6) or IL-12, IL-15,11-18 or GM-CSF have been 
reported to augment humoral immune responses. 
1.2.6.2 Co-stimulatory molecules 
Other investigators have targeted transgene products to lymph nodes or APCs by 
constructing DNA vaccines encoding secreted fusion proteins containing CTLA-4, L- 
selectin or CD40L, whose cognate ligands are present on APCs. By targeting secreted 
antigens for APC uptake, stronger immune responses have been reported (Boyle et al. 
1998; Sin et aL 2000). Similarly, expression of plasmid DNA encoded co-stimulatory 
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molecules (CD80 or CD86) on transfected somatic or APCs can provide critical 
secondary signals for T cell activation, through ligation of cognate receptors 
(CD28/CTLA-4). A number of studies have reported that co-administration of plasmid 
DNA encoding antigen and CD80 or CD86, increased T cell responses without any 
change in the humoral immune responses (Iwasaki et al. 1997; Kim et al. 1997). 
1.2.6.3 Apoptotic molecules. 
Studies have been undertaken to examine the effect of co-immunisation with an apoptotic 
inducing molecule, for example FAS. The in vivo killing of antigen bearing cells in vivo 
directly leads to the increased acquisition of antigen by APCs. This results in an increase 
of antigen specific CTL and the elaboration of T helper-I (Thl) type cytokines and 
chemokines (Chattergoon et al. 2000). 
1.2.7 DNA delivery 
1.2.7.1 Electroporation 
The distribution of plasmid DNA from the site of vaccine delivery and efficiency of 
cellular uptake are the key factors limiting the potency of DNA vaccines. One approach 
to increase DNA delivery is in vivo electroporation. A low intensity of electric pulses 
(100-20OV/cm) delivered from electrodes applied to the muscle or skin has resulted in 
significant enhancement in the cellular and humoral immune responses generated to 
injected DNA vaccines (Kadowaki et al. 2000; Widera et al. 2000). The wide scale 
feasibility, user friendliness and safety of this vaccination approach remains to be 
established. The potential for DNA integration into host genomes 
is a concern. since 
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electroporation results in a much larger copy number of plasmid DNA per cell than that 
achieved by injected naked plasmid DNA (Dupuis et al. 2000). 
1.2.7.2 Gene Gun 
Gene gun technology uses a gas-driven biolistic bombardment device that propels 
particles coated with plasmid DNA directly into the skin (Williams et al. 1991; Tang et 
al. 1992; Fynan et al. 1993). These gold particles are propelled directly into the cytosol of 
target cells, resulting in transgene expression levels higher than those obtained by 
comparable doses of naked DNA and capable of inducing a protective immune response. 
1.2.7.3 Liposomes 
Liposomes are bilayered membranes consisting of amphipathic molecules (polar and 
nonpolar portions) such as phospholipids, forming unilayered or multilayered (lamellar) 
vesicles. Unilamellar vesicles have a single bilayer membrane surrounding an aqueous 
core and are characterised by either being small or large unilamellar vesicles, whereas 
multilayered vesicles have several lipid bilayers separated by a thin aqueous phase. 
Because liposomes can be prepared with significant structural versatility based on vesicle 
surface charge, size, lipid content, and co-entrapment of adjuvants, they offer 
considerable flexibility toward vaccine optimisation. The full scope of the use of 
liposomes to increase the effect of DNA vaccines is currently an active area of 
investigation. Intramuscular injection of plasmid DNA (hepatitis B surface antigen) 
entrapped in liposomes elicited I 00-fold increased antibody titres and increased level of 
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cytokines when compared with those animals injected with naked DNA (Gregoriadis et 
al. 1997). A similar result on antibody augmentation was seen when DNA/liposome 
complexes were administered intranasally (Klavinskis et al. 1999). 
1.2.7.4 Microparticle encapsulation 
Another potential means of DNA delivery is the use of biodegradable polymeric 
microparticles. Plasmid DNA encapsulated by the polymer poly (lactide-co-glycolide, 
PLG) can be delivered by systemic and mucosal routes and has been reported to elicit 
immune responses (Chen et al. 1998; Kaneko et al. 2000) which confer protection in a 
murine rotavirus challenge model (Chen et aL 1998). Adsorption of plasmid DNA onto 
pre-formed PLG microparticles has also been shown to prime for both antibody and 
cellular immune responses (Denis-Mize et aL 2000). PLG mediated vaccine delivery 
appears to act in part, by targeting PLG containing microspheres to APCs rather than 
achieving an increase in gene expression (Denis-Mize et al. 2000). 
1.2.8 Safety Issues 
To date DNA vaccines have been shown to be well tolerated in both pre-clinical and 
phase I clinical trials. Immunopatho logical reactions such as inflammation and general 
immuno suppression have not been observed, although a number of safety concerns 
remain. These include (i) possibility that DNA vaccines could integrate into the host 
genome, which could result in the activation of oncogenes or the inactivation of tumour 
suppressor genes, (n) induce responses against self antigens expressed on transfected 
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cells and initiate autoimmune disease, (iii) induce tolerance rather than active immunity 
to plasmid DNA encoded antigens and (iv) stimulate the production of antibodies to the 
injected DNA. 
1.2.8.1 Potential for Integration 
The Primary safety concem of plasmid DNA vaccines is their potential to integrate into 
the genome of host cells. This could increase the risk of malignancy by either causing the 
activation of oncogenes or inactivation of tumour suppressor genes. If integration occurs 
in germ line cells, there is also a potential for germline transmission. These concerns stem 
from the knowledge that plasmid can integrate at a very low level into cellular DNA 
when transfected into actively dividing cells. Though, it is believed that only a small 
fraction of integration events would alter a gene and prove harmful to a host cell. The 
probability of integration in vivo is likely to be further reduced by physical -chemical 
barriers, which impeded efficient uptake of plasmid DNA in vivo, including 
exonucleases, interstitial DNA-binding proteins and a lower rate of cellular proliferation 
from cells in vitro synchronised for transfection under S phase conditions. Despite 
concerns raised, there is no clear evidence to date that naked DNA vaccines can integrate. 
Gel-purified genomic DNA isolated from many tissues (including germline) following 
intramuscular injection of plasmid DNA and assayed by PCR has found no evidence of 
integration to a detection sensitivity of one copy per ýtg DNA (Ledwith et aL 2000). This 
rate is at least three orders of magnitude lower than the theoretical 
frequency of 
spontaneous gene inactivating mutations (Nicolas et al. 1995). 
Thus for plasmid DNA 
vaccines delivered by intramuscular injection, the risk of mutation 
due to integration 
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appears to be negligible. Other methods of plasmid DNA delivery (including gene gun or 
electroporation) or use novel formulations or adjuvants which increase the efficiency of 
cell transfection could potentially influence the integration frequency. 
1.2.8.2 Potential for induction of immunological tolerance or autoimmunity 
Most vaccines intended for human use are administered to infants and young children. 
Due to the immaturity of their immune system, there is a potential risk that exposure to 
DNA vaccines during the neonatal period may induce tolerance rather than immunity. 
Since protein encoded by a DNA vaccine is produced endogenously and expressed in the 
context of self-MHC, the potential exists for the neonatal immune system to recognise the 
encoded antigen as "self', resulting in tolerance rather than immunity. Consistent with 
this possibility, in one report a plasmid DNA vaccine encoding the circumsporozoite 
protein of malaria (CSP) induced long-lasting tolerance when administered to newborn 
but not adult mice (Ichino et al. 1999). Co-administration of plasmid DNA encoding 
GM-CSF prevented the development of neonatal tolerance in this model (Ishii et al. 
1999). The simplest explanation appears to be that although CpG motifs associated with 
plasmid DNA are responsible for activation of DCs, additional maturation signals are 
required to optimise the response to certain DNA vaccines in neonates. Nevertheless, the 
majority of studies performed to date in rodents and non-human primates have 
demonstrated induction of significant cellular and humoral immunity in neonates 
(Manickan et al. 1997; Sarzotti et al. 1997). Increasing the content of CpG 
oligonucleotides or co-administration of plasmid DNA encoding 
Thl driving cytokines 
(IL-12 or IFN-y) has augmented THI responses where additional DC maturation signals 
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were found to be required in neonates (Kovarik et al. 1999). Overall, neonatal DNA 
vaccines rather than proving tolerogenic are substantially more effective in inducing Th I 
responses than conventional vaccines. 
Another theoretical concern is that autoimmune responses could occur as a result of 
immune-mediated destruction of plasmid DNA transfected cells expressing antigen. 
Cytolysis of antigen expressing cells would release self-antigens for uptake and 
presentation by DCs, theoretically capable of initiating autoreactive T and B cell 
responses. However, presentation of self-antigen occurs during normal cell turnover and 
in the course of viral and bacterial infections, without pathologic sequelae. In this respect. 
It appears unlikely that DNA vaccines would pose any greater risk in initiating organ- 
specific autoimmunity than conventional viral or bacterial vaccines. 
1.2.8.3 Potential for the induction of anti-DNA antibodies 
Concerns that DNA vaccines may promote the development of auto-antibodies to double 
stranded DNA (believed to be the hall mark of autoimmune disease such as systemic 
lupus erthematosus), arises from a series of observations. Bacterial DNA has been 
reported to induce anti-double stranded DNA antibodies in normal mice and to accelerate 
the development of autoimmunity in strains of genetically predisposed to lupus disease 
(Gilkeson et aL 1993). Bacterial CpG can also stimulate the production of IL-6 and block 
apoptosis of activated lymphocytes (Krieg et al. 1995; Klinman et aL 1996), mechanisms 
that may facilitate the persistent activation of B cells and predisposition to the 
development of SLE. Although an increase in IgG anti-DNA secreting cells has been 
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reported immediately following repeated immunisation of normal mice with plasmid 
DNA, the increases were small when compared to the spontaneous production of auto- 
antibodies reported in lupus-prone mice (Mor et aL 1997). Furthermore, the transient 
increase in serum IgG anti-DNA reported did not result in the development of disease in 
normal mice or accelerate disease in lupus prone strains of mice (Mor et aL 1997). While 
the possibility remains that a subset of DNA vaccines encoding determinants cross- 
reactive with self antigens may stimulate an autoimmune response, current data suggests 
that the level of anti-DNA antibody induced by plasmid DNA is unlikely to induce 
systemic autoimmune disease. 
1.2.9 Clinical Trials 
DNA vaccines have entered the clinic for initial safety and immunogenicity testing in 
humans. To date, the potency of the immune responses have been disappointing; 
nevertheless, humoral and cellular have been observed (Roy et aL 2000; Calarota et aL 
2001). Clinical trials of DNA vaccines have been performed or are underway for various 
diseases including cancer, influenza, hepatitis B, HIV and malaria. 
1.2.9.1 HIV 
Phase I clinical trials were initiated to evaluate the safety and immunogenicity of HIV- I 
env/rev DNA constructs in HIV sera-positive and low risk sera-negative individuals 
(Calarota et al. 1998; MacGregor et al. 1998; Boyer et al. 2000; MacGregor et al. 2000). 
NaY-ve healty volunteers who received the highest dose of DNA vaccine demonstrated 
antigen-specific lymphoproliferative responses and antigen specific production of 
IFN-y 
and P-chemokines (Boyer et aL 2000), but these responses were weak and 
did not persist. 
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In HIV sera-positive individuals, a HIV-1 env/rev DNA vaccine construct boosted the 
env specific antibodies. However, no consistent effect was observed on cellular responses 
to HIV. Another phase I clinical trial evaluated HIV regulatory genes, such as rev, nef 
and tat. Immunisation of infected persons with these genes enhanced cellular responses 
but produced no consistent changes in lymphocyte subsets or viral load (Calarota et al. 
1998; MacGregor et al. 1998; MacGregor et al. 2000; Calarota et al. 2001). The DNA 
vaccines were well tolerated in doses from 20[tg up to 2500[ig. No significant local or 
systemic reactions were observed, and no participant dropped out of the study (Le et aL 
2000; MacGregor et al. 2000). 
A phase I trial of an experimental HIV vaccine that includes an HIV A subtype gag gene 
and more than 20 epitopes of DNA encoding regions of HIV proteins is in progress in 
Kenya (Allen et aL 2000). This it he first component of a prime boost vaccination 
strategy and will be followed by a second vaccine using modified Vaccinia virus as a 
vector (Reynolds et aL 1981; Allen et aL 2000). Another phase I clinical trial was 
recently started in infected and uninfected persons to directly compare vaccines in which 
the gene is delivered as naked DNA or by attenuated adenovirus (Cohen 2001). 
1.2.9.2 Hepatitis B 
A DNA vaccine against hepatitis B virus was evaluated for safety and 
immunogenicity in 
a phase I clinical trial involving nalf-ve healthy volunteers. 
A gene gun was used to propel 
the DNA into the skin. The hepatitis B DNA vaccine was 
found to be safe, well tolerated 
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and immunogenic (Roy et al. 2000). All of the volunteers developed protective antibody 
responses of at least lOmIU/ml. The vaccine induced specific CD8+ T cell responses in 
the volunteers who were positive for HLA class I A2 allele. The antigen specific CD8+ T 
cells bound HLA-A2-hepatitis B surface antigens 335 to 343 tetramers, secreted IFN7 
and lysed target cells presenting a hepatitis B surface antigen epitope (Roy et al. 2000). 
1.2.9.3 Malaria 
In a phase I clinical trial of malaria DNA vaccines, three intramuscular injections of a 
Plasmodium falciparum circumporozoite construct induced anti gen-speci fic, CD8+ T 
cell-dependent cytolytic T lymphocytes. The cellular responses were directed against 
multiple epitopes and were restricted by six HLA class I alleles. In the same study, 
despite induction of the excellent cytolytic T cell responses, DNA vaccination failed to 
induce detectable antigen-specific antibodies in the participants (Le et al. 2000). 
In a study investigating the safety and immunogenicity of DNA and modified vaccinia 
virus Ankara (MVA) candidate vaccines, each encoding the malaria DNA sequence 
multiple epitope-thrombospondin related adhesion protein (ME-TRAP), against 
Plasmodium falciparum. DNA ME-TRAP and MVA ME-TRAP when immunised into 
naYve and malaria exposed individuals were safe and 
immunogenic for both CD4+ and 
CD8' T cells induction (Moorthy et aL 2003). 
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1.3 Mucosal Immunity 
The mucosal surfaces of the gastrointestinal and respiratory tracts represent the principal 
portals of entry for most human pathogens. Thus represents a critical component of the 
mammalian immunological repertoire. These include the gut-associated lymphoid tissue 
(GALT), the bronchoepithelium and lower respiratory tract (BALT), ocular tissue, upper 
airway, salivary glands, tonsils and nasopharynx (NALT), larynx (LALT), middle ear 
cavity, male and female genital tracts, mammary glands and the products of lactation. 
The mucosal surfaces are protected from pathogens by non-specific mechanisms such as 
the production of mucus, which forms a physical barrier, and substances such as 
lysozyme, lactoferrin and lactoPeroxidase, which kill micro-organisms or inhibit their 
replication. In addition, the MALT protects the mucosa from exogenous aggression by 
discriminating between fundamental uptake of food or harmless antigens, commensal 
micro-organisms and dangerous pathogens. Thus is able to mount both immunological 
and mucosal tolerogenic responses. 
The mucosal immune system consists of specialised local inductive sites, the organised 
mucosa associated lymphoid tissue (O-MALT), and widespread effector sites, diffuse 
mucosa-associated lymphoid tissue (D-NIALT), both of which are separated from 
mucosal surface antigens by epithelial barriers (Kraehenbuhl and Neutra 
1992). The first 
step in the induction of a mucosal immune response is the transport of antigens across 
the 
epithelial barrier. Following antigen processing and presentation 
in inductive sites, IgA 
committed antigen-specific B lymphoblasts proliferate 
locally and then migrate via the 
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bloodstream to local and distant mucosal and secretory tissues. There they differentiate 
primarily into polymeric IgA producing plasma cells, an important component of D- 
MALT (Kraehenbuhl and Neutra 1992). Dimeric or polymeric IgA antibodies are 
transported across epithelial cells into glandular and mucosal secretions via receptor 
mediated transcytosis (Apodaca et aL 199 1). 
1.3.1 IgA 
Dimeric IgA is the principal class of immunoglobulin found in mucosal and exocrine 
gland secretion. IgA secreting B cells can be activated in both T cell dependent and T cell 
independent mechanisms. The latter is important in producing antibodies that are 
protective against the commensal bacteria that populate the gut and probably represent a 
primitive form of specific immune defence (Macpherson et al. 2000; Fagarasan et al. 
2001). dIgA is composed of two monomeric IgA subunits and a polypeptide J chain, 
although trimers and tetramers are also found. 
Following secretion, dIgA bind to the polymeric immunoglobulin receptor (plgR) that is 
located on the basolateral surface of the epithelial cells that form the mucosa. The plgR is 
a transmembrane protein with an extracellular ligand binding region. After synthesis in 
the endoplasmic reticulum and exit from the Golgi pIgR is a delivered directly from the 
trans-Golgi network to the basolateral surface where it binds dIgA. The pIgR-dlgA 
complex is then endocytosed and transported through a series of endosomal 
compartments across the cell to the apical surface. En route or at the apical surface, plgR 
is proteolytically cleaved and the extracellular binding domain that 
is bound to dIgA is 
released into the mucosal secretions. This cleaved extra-cellular 
domain of the receptor is 
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known as the secretory component (SQ. Secreted dIgA in association with the SC is 
known as secretory IgA (sIgA). Knockout mice that lack pIgR have a significant defect in 
dIgA secretion, although a small but significant amount of dIgA is still formed in bileý 
faeces and intestinal content, which indicates that other pathways for dIgA secretion 
exists (Shimada et aL 1999). 
1.3.2 Epithelial surfaces 
Epithelial linings of different mucosal surfaces differ dramatically. Multilayered 
squarnous epithelia line the oral cavity, pharynx, esophagus, urethra and vagina. The 
intestinal mucosa is covered by only a single cell layer and the airway lining varies from 
pseudostratified to simple epithelium. These diverse epithelia are not impenetrable 
barriers, but are cell assemblies that control cross-talk between the exterior and interior 
using multiple antigen sampling strategies. In stratified and pseuclostratified epithelia, 
antigen processing dendritic cells serve as motile "scouts" that move into the epithelium, 
obtain samples of luminal antigens and migrate back to local or distant organised 
lymphoid tissues. In simple intestinal and airway epithelia where the intracellular spaces 
are sealed by tight junctions, specialised epithelial M cells deliver samples of foreign 
material by transepithelial transport from the lumen to organised lymphoid tissues within 
the mucosa. 
1.3.3 M Cells 
M-cells represent specialised epithelial cells that actively transport soluble and particulate 
matter across the epithelium (Gebert et aL 
1996). Thereby, performing a "sampling" of 
luminal antigens so that cells of the immune system come 
into contact xN ith potential 
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pathogens (Neutra et aL 1996). M cells thus combine two important functions 
maintenance of the barrier and initiation of mucosal immune reactions. However, 
organisms such as Poliovirus, Rotavirus and Salmonellae can subjugate this machinery 
(Neutra et aL 1996). 
The transepithelial transport of substances by M cells is preformed by fluid phase or 
receptor-mediated endocytosis at the apical membrane, transport in vesicles across the 
cytoplasm and exocytosis to the basolateral membrane (Neutra et al. 1987). The 
basolateral surface is deeply invaginated to form large intraepithelial "pockets" into 
which transcytosed particles and macromolecules are delivered (Neutra and Kraehenbuhl 
1992). This unique structural modification is supported by an extensive array of 
inten-nediate filaments and is lined by a distinctive "pocket domain" of the plasma 
membrane (Neutra et al. 1987). The pocket and its content of immigrant cells is a 
cardinal feature of the M cell. M cells also have basal processes that extend 10ýtm or 
more into the underlying lymphoid tissue where they could make direct contact with 
lymphoid or antigen presenting cells (Giannasca et al. 1994). 
The immigrant cells in M cell pockets have been identified by immunocytochemistry of 
intestinal Peyer patches of rodents, rats and humans (Ermak and Owen 1986; Ermak et al. 
1990). In all species, both B and T lymphocytes were present along with a small number 
of macrophages. Most of the T cells were CD4+, and none 
displayed the gamma/delta T 
cell receptor of villus intraepithelial lymphocytes 
(IELs)- Human M-cell associated T 
cells displayed the marker antigen CD45RO typical of memory cells, although 
in some 
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specimens naive T cells were observed (Farstad et aL 1994). B cells in the pocket 
expressed the "naive" cell marker CD45RA along with HLA-DR suggesting that the M 
cell pocket is a site of interaction between T cells and antigen presenting B cells. The B 
cells contained IgM but neither IgG nor IgA, suggesting that B memory cells and initial B 
cell differentiation may also occur here. Since the B cells in the M cell pockets are the 
same types as the subepithelial B cells associated with the underlying follicle, it has been 
suggested that B lymphoblasts traffic into the M cell pocket allowing for continued 
antigen exposure, thus extending and diversification the immune response (Farstad et al. 
1994). 
1.3.3 GAILT 
One of the best studied sites of mucosal immunology is the gut associated lymphoid 
tissue (GALT). Lymphoid cells are found in three regions within this tissue. The outer 
mucosal epithelial layer contains IELs. The majority of these lymphocytes are CD8+ T 
cells that express 76 T-cell receptors. The lamina propria, which ties under the epithelial 
layer, contains large numbers of B cells, plasma cells, activated TH cells, and 
macrophages in loose clusters. Finally, within the sub-mucosal layer of the intestinal 
lining are nodules consisting of 30-40 organised lymphoid follicles, called Peyer's 
patches. 
The common feature of GALT includes an epithelial surface containing 
M-cells 
overlying organised lymphoid follicles. Mucosal epithelium 
has a unique structure, and in 
addition to M cells, it also contains mucin producing glandular cells. 
lymphocytes, 
plasma cells, dendritic cells and macrophages. 
The dendritic cells are present in different 
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components of the common mucosal immune system, including both the organised 
lymphoid tissue and the mucosal epithelium. These cells can be strongly associated \N ith 
potentiation of the immune response whether by inducing active immunity (Liu and 
MacPherson 199 1; Liu and MacPherson 1993) or tolerance (van Ginkel et aL 2000). 
Following exposure of an antigen and its uptake via M-cells, there is a variable degree of 
activation of T cells, DCs and B cells, especially of the IgA isotype. Activation of T cells 
results in the release of a number of distinct cytokines and chemokines from different T- 
cell subsets and recognition of antigenic epitopes including MHC class I and 11 
molecules. 
1.3.2 NALT 
NALT is similar in its morphological and functional characteristics to other mucosal 
tissues such as the GALT and BALT; however, it has better developed lymphoid 
follicles, with marked intraepithelial infiltration by lymphocytes and dendritic cells. 
NALT resembles Peyer's Patches with regards to ontogeny although PP appear shortly 
before birth, earlier than NALT. This may possibly be due to a more central role for the 
PP or may simply result from earlier exposure of the gut to foreign antigens. The 
activated appearance of both NALT and PP is suggestive that they are the main 
components in the defense of the respiratory tract and gut respectively. The functions of 
NALT and PP may differ, with the PP being the central tissue in the induction of 
secretory Ig synthesis, while the lymphoid tissue in the respiratory tract appear to 
be 
more involved in cellular responses. The respiratory tract can 
be broken doýN n into NALT 
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and BALT, and appear to differ in their state of activation and in the number of B cells 
that express membrane IgA. BALT more closely resembles PP in the frequency of these 
cells, where as in NALT, they are quite rare (Butcher et al. 1982; Plesch 1982). The 
follicular areas are organised into B cells and intrafollicular (T-cell) areas of 
approximately similar size. In the mouse, lymphoid aggregates called the O-NALT is 
located on the palate at the entrance to the naso haryngeal duct, and the less well p 
organised diffuse lymphoid tissue lining the nasal passages (D-NALT) (Liang et al. 
2001). Particulate antigens may be removed quickly from the nasal mucosa by the 
mucociliary system. However, when the antigens succeed in adhering to the epithelium 
they are taken up by M cells. The NALT M cells appear to be identical to those in 
Peyer's patches and BALT and are involved in similar immunological functions 
including antigen uptake and subsequent mucosal immune responses to specific antigens 
(Park et al. 2003). 
The nasal mucosa is drained by the superficial cervical lymph nodes (CLN) which in turn 
drain to the posterior CLN. However, large doses of antigenic material may drain directly 
to the posterior lymph nodes. Although the nasal mucosa drains to the superficial cervical 
lymph nodes, NALT drains preferentially to the posterior cervical lymph nodes (Tilney 
1971; Koomstra et al. 1991). Antigenic stimulation of the mucosal immune system is 
known to induce specific local immune responses, notably the production of secretory 
immunoglobulins and to result in specific systemic tolerance. A study examining the 
repeat intranasal inoculation of ovalbumin observed that tolerance was established 
(Holt 
et aL 1987). The superficial CLNs that 
drain the nasal mucosa are the site of suppressor 
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T-cell induction and activation, and may play a role in the generation of tolerance. Single 
intranasal immunisation evoked almost no response in either serum or in BALT. NALT. 
posterior and superficial CLNs and spleen. A second intranasal immunisation with a 
soluble T-cell dependant antigen resulted in a distinct response in the serum and in the 
draining posterior CLN only (Holt et al. 1987). 
1.4 Hypothesis to be tested 
The need to improve the efficacy of plasmid DNA immunisation is still of prime 
importance. As the immune system is constantly being elucidated, potential candidates 
for genetic adjuvants or delivery vehicles are being identified. To overcome the hurdle of 
the dose per Kg of DNA required to initiate immunity to a specific antigen. new 
techniques are investigated to enhance the immune responses. In this study we have 
examined the use of different encapsulation methods as well as the use of a genetic 
adjuvant to increase the efficacy of plasmid DNA delivery. 
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Chapter 2- Materials and Methods 
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2.1 Plasmid DNA Preparation 
2.1.1 Propagation of Plasmid DNA 
Exo1i transfected with the plasmid of interest (Table 1) were streaked from a glycerol 
stock onto an LB Agar plate (recipe Appendix 1), containing the appropriate antibiotic 
selection (Table 1). Streaked plates were grown ON and all subsequent cultures 
inoculated from single colonies not more than 48 hours old. 
2.1.2 Mini preparation of plasmid DNA 
A single colony (Section 2.1.2) was inoculated into Iml of Terrific Broth, and grown for 
4 hours at 37'C. The bacteria were pelleted at 1650g in GSA rotor (RC5C, Sorvall 
Instruments). The pellet was resuspended in 100[d of Solution I (see Appendix 1, 
containing 5pl of 10mg/ml RNAse A), incubated for 5 minutes at room temperature, 
followed by addition of 200pl of Solution 2, and mixing the contents by gently inverting 
the tubes (5 or 10 times). After a5 minute incubation on ice, 150ýtl of solution 3 was 
added and mixed gently (by inverting the tube 5-10 times) and incubated for 15 mins on 
ice. Tubes were centrifuged at 16K g for 5 mins in a Biofuge pico (Heraeus), 
supernatants were removed and extracted with 400[d phenol -chloroform. 
DNA was 
precipitated bY the addition of 2 volumes of ethanol and 
0.1 volume NaAc for I hour at - 
201C, and pelleted at 16K g. Pellets were ethanol washed, air 
dried and resuspended in 
TE. The optical density was determined at 260nm and 
280nm. 
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2.1.3 Maxi Preparation of Plasmid DNA. 
An overnight culture seeded from a single colony (section 2.1.2) was diluted I in 1000 
into IL of 2xYT and grown until the absorbance was 1.2 at 600 nm. Cultures ý\ere 
centrifuged at 1650g, for 15 minutes at 4'C in a GSA rotor (RC5C, Sorvall Instruments), 
and the pellets resuspended in l8mls Solution I (see Appendix 1) for 10 minutes (all 
procedures were performed at room temperature unless otherwise stated) followed bý- the 
addition of 40mls Solution 2 (see Appendix 1). After 10 mins, 20ml of ice cold Solution 
3 (see Appendix 1) was added and incubated on ice for 10 mins and centrifuge at 80OOg 
for 30 minutes at 4'C in SS-34 rotor (RC5C, Sorvall Instruments). DNA was precipitated 
with 0.6 volume of propanol (BDH) and centrifuge for 20 minutes, at 9500g in the SS-34 
rotor. Supernatants were decanted and the pellet washed with 70% Ethanol and air-dried 
for 5 minutes. The pellets were resuspended in TE (see Appendix 1), containing I mg/ml 
of caesium chloride (ICN). To this 0.6 volume of ethidium bromide was added, and then 
the solution was centrifuged at 80OOg for 20 minutes at 4'C in SS-34 rotor. The 
supernatants were transferred to sealable Ultra Crimp Beckman tubes, balanced, sealed 
and centrifuged for 16 hours at 65,000rpni in T8-90 rotor with a Discovery 100 
Ultracentrifuge (Sorvall). The caesiurn chloride gradient caused bands to be formed, with 
the upper band being nicked plasmid DNA, and the lower being supercoiled plasmid 
DNA The lower band was harvested using a needle and syringe, transferred to a new 
centrifuge tube, balanced, resealed and spun for another 16 hours at 65,000rpm. The 
ethidium bromide was separated from the plasmid DNA by repeated extractions ýý 
ith an 
equal volume of Butan-l-ol (BDH) vortexing and centrifuging at 
1500rpm for -3) minutes 
until it was visibly removed from the upper aqueous 
layer. Any remaining organic 
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solvents and the CsCl were removed by dialysis over 48 hours with at least 4 changes in 
dialysis buffer (see Appendix 1). Protein and organic contaminants were removed b\ 
phenol chloroform extraction, centrifuged for 6 minutes at 3500 rpm (2537g) in a 
RTH750 rotor (RT7 Plus Centrifuge, Sorvall). DNA was precipitated xNI-ith 2.5 volume 
100% Ethanol (BDH) at -70'C (for a minimum of 2hr) followed by centrifugation at 
3500rprn for 10 mins at 4'C. The DNA was washed with 70% ethanol, and vacuum dried 
using a Concentrator 5301, (Eppendorf). The pellet was resuspended in pyrogen free 
water and the concentration of and purity of the plasmid DNA was determined by 
spectrophotometric analysis at 260 and 280nm respectively using a Ultrospec 3000 
(Pharmacia, Biotech). An absorbance of I at 260nm is equal to 50ug/ml of double 
stranded DNA, and DNA preparations were rejected if the OD 260/280 ratio ,, vas below 
1.8. 
2.1.4 Restriction Enzyme Digestion of plasmid DNA 
Restriction enzyme digestion was used to verify the correct cDNA insert in each 
preparation of plasmid DNA. Restriction enzyme digestions were performed using the 
NEB system. Iýtg of DNA, was added to 2ýtl 10x buffer (NEB), 10 units of enzyme 
(I 
unit [NEB]), the volume was made up to a total of 20ýil with 
distilled water, and digested 
for I hour at 37C. The plasmid was visualised on a 1% agarose gel 
(1% agarose in TAE, 
with ethidiurn bromide at 2ug/ml) using a 
Flowgen Submarine electrophoresis apparatus. 
DNA was electrophoresed for 40 minutes at 
80volts, and visualised using a UV 
Transilluminator (UVP). 
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2.2 Transfections of Eukaryotic cells 









VR SEAP Kanamycin Vical 
HIV-Gag Kanamycin 
Luciferase Kanamycin 
pcDNA3. I+ CCL20 Ampicillin Invitrogen 
HIV-Gag Ampicillin 
pTRE-Shuttle HIV-Gag Ampicillin Clontech 
PCi SEAP Kanamycin Promega 
Table I- List of the plasmid DNA used in this study, including the backbone vector, the 
insert, the antibiotic resistance and the company where the vector was purchased. 
2.2.2 Cell transfections with plasmid DNA 
HEK293T (ECACC no: 85120602), a human embryonic kidney cell line was transfected 
to determine the transduction efficiency of naked or complexed plasmid DNA 
preparations. Cells were plated at a density of IX 105 cells per well in a 24 well plate 
(Costar) in DMEM (see Appendix 1) subsequently called DMEM+, and incubated at 
370C in 5%CO2. After 16 hours the supernatant was removed, and the cell monola\er 
was washed with phosphate buffered (PBS - see 
Appendix 1) The PBS was removed and 
300[il of either naked DNA, DNA/lipid complexes or 
DNA/peptide complexes ý\as 
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added very slowly to each well. The cells were incubated at 37'C for 2 hours, and then an 
equal volume of 300[tl 2x concentration of DMEM+ was added per \ýell. and cultured for 
a further 48hours. 
2.2.3 Lipids under investigation in the study 
The lipids used in the study were kindly supplied by Vical Inc, San Diego. 
Lipid Name Chemical composition 




DMORIE: DpyPE Aminopropyl-dimethyl-myristoleyloxy-propanaminium 
(Vaxfectin) bromide/diphytanoylphosphatidyl -ethano lam ine 
Table 2- List of cationic lipids used in this study, and there chemical structure. 
2.2.4 Complexing of DNA with lipid 
The amount of transfection agent to DNA was calculated in molar ratios. The molarity of 
DNA is calculated based on the average weight of a single nucleotide; I mole is 
equivalent to 333g of DNA in IL. Therefore, DNA at Img/ml will have a concentration 
of 3.33mM. The lipids, GAP-DMORIE: DpyPE, DMRIE: DOPE, and Gap: DLRIE were 
formulated at 1.5mM in double distilled water. A well in a 24 well plate, 
is typically 
transfected with I [ig of DNA. Therefore, at a ratio of 1: 1,1 ug of DNA 
is complexed with 
2pl of lipid (calculation =: (DNA concentration/lipid concentration) when 
DNA =I mg/ml 
for lug of DNA). To complex, lipids were diluted 
in saline, and then added dropwise to 
an equal volume of DNA which was also 
diluted in saline. The two Nýere mixed bý 
flicking the tube after each drop, not by vortexing. 
After the two components ý\ere 
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thoroughly mixed together they were incubated for 30minutes at room temperature. The 
volume was then increased to 300ýtl (the amount added to a 24 well plate) with DMEIO 
without any additives. 
2.2.5 Peptides investigated in this Study 
The peptides were synthesised by Cambridge Research Biochemicals to a 99% purity as 
determined by HPLC. 
Peptide name Sequence 
Molecular Weight 
(Daltons) 
Antennapedia-K 16 RQIKIWFQNRRMKWKKGGGKKKK 4468.7 KKKKKKKKKKKK 
Antennapedia RQIKIWFQNRRMKWKK 2417.9 
Polylysine-Molossin ICRRARGDNPDDRCTGGGKKKKKK 3797 KKKKKKKKKK 
Table 3- List of peptides investigated in this study, their amino acid constituents and 
their molecular weight. 
2.2.6 Complexing DNA with peptide 
Peptides were dissolved within PBS, lOmM Tris Saline, ImM HEPES Saline, 
Saline or 
DMEM (without additives), at a concentration of lmg/ml, which is equivalent to 
0.22mM 
Antennapedia-K16,0.26mM Polylysine-molossin and 0.41mM Antennapedia. In a 
24 
well plate, each cell was transfected with 
I ýtg of plasmid, in a total volume of 
300 [il. Complexes were formed in 15ml conical 
tube (Coming), where plasmid was 
diluted in DMIEM without additives. The peptide was added at the required concentration 
during vortexing of the plasmid solution. 
For example, at a 1: 1 molar ratio of 
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DNA: antennapedia-K16, the DNA is 3.33mM, the peptide is 0.22mM. So for IýIg of 
DNA, you would need 13.6ýtg of peptide, and for a 6: 1 ratio, you would need 21-7ýtg of 
peptide. The DNA: peptide complex was incubated for 30minutes at room temperature, 
and was then added to the cells and reincubated at 37C. After 2 hours, the supernatant 
was removed, the cells were washed, and I ml of DMEM+ was added per well. 
2.3 Reporter Assays 
2.3.1 Generation of Standard Curves. 
Standard curves were generated with the appropriate recombinant enzyme. A range of 
standards were created, for luciferase, the range was log dilutions starting at lOng per ml 
to Ipg per ml of recombinant luciferase (Sigma), for SEAP, the range was halving 
dilutions from lug per ml to 7.8125ng. of recombinant SEAP (Calbiochem). Each dilution 
was done in duplicate, the averages were plotted, and a standard curve was generated. 
The equation for the curve was calculated, and experimental values were obtained. 
2.3.2 Luciferase (reporter gene) assa: E of cell lysates. 
Test samples were compared against a standard curve generated in each assay of known 
concentrations of recombinant luciferase (Sigma UK). Cell lysates were generated b". I 
adding 200pI of Cell Lysis buffer (Promega, UK) to the cell monolayer 
in a 24 ýý ell plate. 
After 5 minutes, the cell monolayer was removed, and centrifuged at 
13,000rpm 
(I 5.8x 103g) for 2 minutes. 20pl of the cell lysate supernatant was added to 
I 00ul of 
Luciferase Assay Reagent (Promega, UK). Luminescence was 
immediately measured for 
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Iminute on a Turner TD20e luminometer. The concentration of luciferase in the samples 
was expressed as pg of luciferase protein, as determined from the standard curve. 
2.3.3 Secreted Alkaline Phosphotase (SEAP) assay of supernatants. 
Supernatants were heat inactivated at 560C for 30mins, to remove endogenous SEAR A 
standard curve was established using recombinant SEAP (Calbiochem) (Section 2.2.6). 
50ýtl of supernatant or recombinant SEAP was added to 200pl of SEAP substrate (see 
Appendix 1). Readings were taken at 2,5,10,15,30 and 60 minutes at 405nm with a ý, 
correction of 605nm with an Anthos 20 10. 
2.3.4 Flow Cytometric AnalysiS of Green Fluorescent Protein 
At 48 hours following transfection with either gWiz-GFP or VR-GFP. Cells were washed 
with PBS, and followed by two washes with FACS (see Appendix 1), then fixed ýý, Jth 
300ul 1% paraformaidehyde (PFA) (Sigma, UK). Cells were analysed with a Coulter 
flow cytometer, and data was processed using WinMDI v2.8 (Copyright Joseph Trotter). 
2.3.5 HIV Gag flow cytometry 
Cells were transfected with gWiz-Gag, Vical-Gag, pcDNA-Gag, and a pTRE-Shuttle. 
Cell monolayers were washed with PBS and removed from the wells using 
FACS buffer, 
spun down in LP4 tubes (LIP) 500g, at 4C for 5 mins 
in a H6000A rotor (ROC, Sorvall 
Instruments). Cell were fixed by resuspension in 1% PFA in PBS 
for 15 minutes. washed 
twice with FACS buffer, and then permeablised with 
0.2% Saponin in PBS for 15 
minutes at room temperature. After 
3 washes with FACS buffer, a murine anti-human- 
Gag antibody (1/100) in 100ul was 
incubated with the cell suspension for I hour on ice. 
After 4 washes with FACS buffer, a goat anti-mouse-PE 
(1/50) ýN as incubated ý\ith the 
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cells for I hour on ice. Cells were washed 5 times with FACS buffer. and resuspended in 
300ul FACS buffer. Cells were analysed on an EPICS XL MCL (Coulter), and data ý\ as 
processed using WinMDI v2.8 (Copyright Joseph Trotter). 
2.3.6 SDS PAGE and Western blot of transfected cell lysates and supernatants 
Cell lysates (containing both cytoplasmic and membrane fractions) were prepared ýý ith an 
equal volume of reducing sample buffer (See Appendix 1) and boiled for 3minutes at 
100'C. 20ul of boiled samples were loaded per well of a 10% polyacrylamide gel (See 
Appendix 1) with a 5% stacking gel (See Appendix 1). Samples were electrophoresed 
using a Biometra P25 power pack, at 80 volts constant voltage for 2 hours. The separated 
proteins were electroblotted onto Hybond C-Super nitrocellulose membrane (Amersham 
UK) at 240mA for 2 hours using a Transphor Electrophoresis Unit (Hoefer, UK) in 
transfer buffer (see Appendix 1). The membrane was washed twice in Tris Buffered 
Saline pH 7 (TBS - see Appendix 1) containing 0.1% Tween-20 (called TBS-T) for 5 
minutes and blocked overnight at 4'C in TBS-T containing 5% FCS. A primary antibody. 
anti-murine CCL20 (R&D Systems) was diluted 1/500 and preincubated in TBS-T with 
5% FCS for I hour, and then incubated with the membrane for 2 hours. Unbound 
antibody was removed by washing 3 times for 10 mins in TBS-T. Bound antibody was 
defected by incubating the membrane with a Horse Radish Peroxidase (HRP) conjugated 
antibody (Sigma, UK), diluted 1/1000 in TBS-T containing 
5% FCS for 2 hours, 
followed by 4 washes in TBS-T, the membrane was developed with 
Enhanced Chemi- 
Luminescence (ECL) reagents (Amersham, UK) and exposed onto 
Hyperfilm-ECL 
(Amersham, UK) for 10 seconds, 30 seconds, I minute, and 
2 minutes. 
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2.3.7 Transwell Chemotaxis Assay 
The chernotactic ability of bone marrow derived DCs (BN4DCs) was analysed using 
ChernoTx system according to the manufacturer's instructions (96-well ChemoTx 
chamber; Neuro Probe, Inc. ). In brief, BMDCs were resuspended in RPMI 1640 
supplemented with 1% FCS and 25 mM Hepes. Supernatants from HEK293 cells 
transfected. with pcDNA3.1-CCL20 for 48 hours or recombinant CCL20 \\ere placed in 
the lower chamber, and a filter with 5-ýtm pore size was placed on top. Aliquots of 2x 1 04 
cells/well were applied to the filter's top surface, and the plate was incubated at 37C in 
5%CO2for 4 h. The cells migrating to the bottom chamber were counted with an inverted 
microscope in five or more non-overlapping fields (magnification 40). 
2.3.8 Calcium Flux Assay 
Calcium Flux assays were carried out upon Rat splenocytes and HEK293T cells stably 
transfected. with either human CCR6 or murine CCR6. Rat splenocytes were harvested 
from a Lewis Rat, and homogenised into a single cell suspension by grinding through a 
sieve in RPMI+ (see Appendix 1). To remove adherent cells, the splenocytes were passed 
through a nylon column, leaving the T and B cell populations. HEK293 cells stably 
expressing hCCR6 or mCCR6, or the rat splenocytes were suspended 
in IX 107/Ml in 
DMEM with 10% foetal calf serum. The cells were 
loaded with 3 ýiM Indo-I 
acetoxymethyl ester (Molecular Probes) at room temperature 
in the dark for 45 min. The 
loaded cells were washed and resuspended 
in Hank's balanced salt buffer ýý, ith I% foetal 
calf serum at the same concentration. 
Calcium mobilization of Ix 10 
6 cells ýNas measured 
in 2 ml of Hanks' balanced salt solution with 
1.6 mM CaC12 in a continuousl. % stirrim-1 
acrylic cuvette at 371C 
in a Photon Technologies spectrofl uori meter 
(Princeton). The 
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fluorescence was monitored as ratio of emission at 405 and 483 nm at an excitation 
wavelength of 350 nm. The chemokines examined were added at the concentrations of 
200nM or 5 OOnM recombinant human or murine CCL20 or 20nM SDF- I (x. 
2.4 In vivo studies 
2.4.1 Mice 
All procedures were performed with seven to eight week old female Balb/c mice (Harlan 
Olac, Bicester, UK), with a weight not less than 18g. Animal care throughout the study 
was in accordance with UK Home Office guidelines. 
2.4.2 Intranasal immunisation. 
Cytofectins, GAP-DMORIE: DpyPE or DMRIE: DOPE were complexed with plasmid 
DNA to increase the efficiency of DNA uptake for intranasal delivery. Typically, doses 
of plasmid DNA ranged from 40[tg to 100ýtg with complexing ratios ranging from 4: 1 to 
16: 1 molar ratios. In accordance to Home Office guidelines, the maximum volume 
administered was 60pl, over a minimum of 2 hours. Complexing was achieved by a 
similar method as in section 2.2.4. Briefly, plasmid DNA and lipid were each diluted in 
saline to 50% of the final volume required for the immunisation. The lipid was added to 
the DNA dropwise, with thorough mixing by flicking the tube after each addition, thus 
leaving a cloudy solution with a minimal amount of precipitation. Depending on the 
overall volume required for immunisation, a minimum of 5ýd to a maximum of 12pl Ný as 
applied to the nares at one time, with a maximum of 5 applications allowed. 
Dosage to 




2.4.3 Intramuscular Immunisation. 
Plasmid DNA was made up to a maximal concentration of Irng/ml in saline. The mice 
were anaesthetised with Halothane (Sigma), and kept anaesthetised bY the use of a mask. 
50ýtl of the plasmid DNA solution was injected into the calf muscles of the tx\o hind 
limbs. 
2.4.4 Subcutaneous Immunisation 
50[tl of DNA at I mg/ml in saline was inoculated by the subcutaneous route at the base of 
the tail. 
2.5 Tissue Isolation 
2.5.1 Generation of Bone Marrow Derived Cells 
Femurs and tibiae from Balb/c mice were harvested, and the surrounding muscle was 
dissected from the bone. Both ends of the bone were cut, and the marroxv ýýas flushed 
through the bone with RPMI+ (see Appendix 1) using a needle. Clusters within the bone 
marrow were disintegrated by vigorous pipetting. Bone marrow was seeded at 2x 106 cells 
per 100mm dish in 10mls of RPMI+ containing 50ýM 2-mercaptoethanol (Sigma) and 
20ng/ml recombinant GM-CSF (Peprotech) and cultured for 6 days at 37'C. 
2.5.2 Nasal Associated Lymphoid Tissues. 
The head was severed from the bodies and the skin and the eyes were removed. 
The 
cranium from just behind the eyes, and the 
brain, Nvere removed, as was the loý\ er jax\, 
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leaving the nasal passages. Extra bone was trimmed away. leaving a minimal amount of 
bone and tissue. 
2.5.3 Luciferase expression in NALTS. 
The isolated bony nasal cavities were ground to a powder using a pestle and mortar under 
liquid nitrogen and dissolved in cell lysis buffer, to give a Img/ml concentration 
(determined by weight of tissue). After vigorous vortexing, the lysates were incubated on 
ice for 5 minutes, centrifuged at 16K g for 5 minutes and supernatants were collected. 
20ýil of supematant was added to 100ýil of Luciferase Assay substrate (Sigma). 
Luminescence was immediately measured for I minute on a Turner TD20e luminometer. 
The concentration of luciferase in the samples was expressed as pg of luciferase protein. 
as determined from the standard curve (2.2.6). 
2.5.4 Flow cvtometric analysis of NALT tissue. 




Molecule e s 
CDI Ic HU IgG PE 0.5pg Pharmingen 
CDI lb, MI/70 IgG2b Biotin 0.5pg Pharmingen 
CD16/32 2AG2 IgG2b Pure 0.5pg Pharmingen 
Southern 
MHC class 11 NIMR-4 IgG Biotin 0.5ýtg 
Biotechnology 
Associates Inc. 
Streptavidin Cy-Chrome 0.5ýig Pharmingen 
Kindl,,. supplied 
1/20 by Dr 
C. Power, 
CCR6 IgG FITC dilution Serono Pharmaceuticals. 
SxN itzerland 




The NALT was harvested by piercing the nasal cavities and scraping out all nasal tissue 
into RPMI+ (see Appendix 1). The tissue was disassociated with fine needles, into a cell 
suspension and cells were counted, maximally 6xI 05 cells were recovered Per mouse. 
2xlO 5 cells were aliquoted into LP4 tubes (LIP) and washed twice with FACS buffer. 
Cells were blocked with antiCD16/CD32 (BD Pharmingen) at 1/100 dilution for 15 
minutes, and primary antibodies were added in I 00gl for I hour. Cells were washed three 
times with FACs buffer, and if required, a streptavidin secondary (1/100) was added 
100p] per tube, and incubated on ice for 30minutes. Tubes were washed for a minimum 
of three times. Cells were analysed on an EPICS XL MCL (Coulter) flow cytometer, and 
data was processed using WinN4DI v2.8 (Copyright Joseph Trotter). 
2.5.5 Isolation and immunofluoreseence stainint! of NALT DC. 
The heads from experimental and control mice were collected following exsanguinations 
under terminal anaesthesia. Tissue was trimmed to the nasal cavity and cell suspension 
isolated by teasing through a sieve in RPMI+. Mononuclear cells were purified by 
centrifugation through a 75% and a 40% percol gradient. Cells from the interface were 
washed in FACs buffer counted and stained. The cells were incubated with anti 
CD I 6/CD32 receptor block (BD Pharmingen) at 1: 100 for 15 minutes and then stained 
with CD IIc biotin (BD Pharmingen) at 1: 100 for I hour at 4'C. After 3 washes NN Ith 
FACs buffer, biotin labelled cells were revealed using streptavidin conjugated PE-Q, 5 
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(BD Pharmingen) at 1: 100 dilution. Cells were washed 5 times in FACs buffer to remove 
excess streptavidin, and then sorted based on their CD IIc expression on a Mo-Flo high- 
speed multi-laser sorter (Cytomation). CDI Ic expressing cells were cytosmeared onto in 
situ PCR Glass slides (Perkin Elmer), and fixed in pre-chilled acetone at -701C for 
15minutes. Slides were washed in PBS, and then blocked with normal rabbit serum 
(Vector Laboratories) at 1: 100 for 15 minutes, followed by staining xvith a rabbit anti- 
GFP FITC poly-clonal antibody (Sigma) (1: 100) for I hour. Cells washed x\ith PBS. and 
then examined by immunofluorescence camera (Photonic Sciences. Nikon) 
2.5.6 RNA isolation from NALT 
NALT was ground up to a fine powder under liquid nitrogen using a pestle and mortar 
and resuspended in Iml TRIZOL (Invitrogen) for 50-100mg of tissue, and incubated for 
15 minutes at room temperature, then centrifuged at 13,000rpm (I 5.8x 103g) for 10 
minutes. The supernatant was removed, and 0.2ml of chloroform (BDH) was added to 
Iml of TRIZOL containing supernatant. Tubes were shaken vigorously for 15 seconds, 
incubated for 2 minutes at room temperature, and then centrifuged for 15 minutes at 
13,000rpm (15.8x] 03 g). The RNA from the aqueous phase, was removed to a fresh tube 
and precipitated with 0.5ml isopropanol (BDH) to Iml of starting TRIZOL. Samples 
were incubated at room temperature for 10minutes, and then centrifuged at 13,000rpm 
(I 5.8x 103g) for 10 minutes and then the RNA pellet ,, x as washed twice xvith 70% ethanol, 
and resuspended in Diethyl cyanophosphonate 
(DEPQ treated water (Sigma). RT-PCR 
was carried out as the ProSTAR 
First-Strand RT-PCR Kit (Stratagene). Briefly, 5ýtg of 
RNA was diluted into 38ýd with 
DEPC treated water. To this 3ýd of random primers 
(100ng/l, d) was added, and mixed gently. 
The reactions x\ere incubated at 650C for 5 
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minutes, and then were allowed to cool until room temperature. to allow the primers to 
anneal to the RNA. Into this reaction, the following was added in order. 5ýtl of I Ox first- 
strand buffer, lgl of RNase Block Ribonuclease Inhibitor (40U/gl). 2pl of 100mM 
dNTPs and I ýLl StrataScript reverse trascriptase (50 U/ýtl). The reactions were incubated 
at 90'C for 5 minutes, and then placed on ice for the PCR reaction. 3ýtl of the cDNA 
produced was placed in a separate tube, and the following was added in order. 10pl of 
lOx Taq DNA polymerase buffer, 0.8ýtl of lOOmM dNTPs, 2ýil of 10ýtM forward 






T7 promoter TAATACGACTCACTATAGGG 
HPRT-Forward CGATGATGAACCAGGTTATGACC 
HPRT-Reverse CCTTTCCAGTTAAAGTTGAGAGATC 
Table 5- List of primers used in this study. 
The reactions were heated to 91'C for 5 minutes, then cooled to 54'C for 5 minutes. 
before being pulsed centrifuged, and having 0.5ýtl of Taq DNA polymerase (5U/ýil) 
added. Mineral oil was carefully overlaid on top of the reaction, and then placed onto the 
PCR block, for 30 cycles of 9PC for I minute, 54'C for I minute and 72'C for 2 
minutes. On completion, the reaction was 
incubated at 72'C for 10 minute. The PCR 
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product was analysed on a 1% ethidium bromide stained agarose gel. and product sizes 
were identified using DNA markers (Stratagene). 
2.6 Immunohistochemistry 
2.6.1 Immunohistochemistry of tail sections. 
50ýtg of plasmid DNA encoding CCL20 was injected subcutaneous into the base of the 
tail. After, 24,36,48, or 72 hours tails were harvested, and mounted on OCT. At least 3. 
10 micron sections were analysed per time point, per tail. The area around the section 
was scored with a diamond pen. Sections were placed in acetone for 30 minutes and then 
washed in TBS. Within a humid chamber, the section was washed 3 times with TBS. 
Excessive liquid was removed from the sections and the antibodies diluted in TBS were 
applied to the scored area. The antibodies used were biotin conjugated- MHC class 11 
(Southern Biotech, Clone: NIMR-4, Rat IgG) and CD11c (Pharmingen, Clone HL3, 
Armenian Hamster) diluted 1: 100. After aI hour incubation, the section was washed 
with TBS, and the section was incubated with a 1: 1000 Streptavidin-Alkaline 
phosphatase (Sigma) diluted in TBS, and incubated for 30minutes. After washing with 
TBS, Alkaline Phosphatase buffer. The Alkaline phosphatase buffer (see Appendix 1) 
made fresh each time, and filtered before use After 15-20 minutes, the substrate was 
removed by washing for 2 minutes with water. Sections were counterstained in 
Haernatoxylin for 2 minutes, and then washed in water for 20 minutes. Slides were 
mounted using Aquamount, blinded and counted under a microscope. 
Each section had 5 
fields of view counted for positive cells, 3 sections counted per mouse, and 3 mice 
counted per time point. 
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2.6.2 Immunohistochemistry of NALT 
The heads from experimental and control mice were removed following exsanguinations 
under terminal anaesthesia and fixed for at least 24 hours in 10% formalin (Sigma, UK). 
After rinsing in EDTA decalcification solution (0.43M EDTA, pH 7), the head was 
trimmed to leave the nasal passages. The heads were re-immersed in EDTA 
decalcification solution at 370C for at least 7 days, rotating slowly. The incisors were 
removed, and the heads were rinsed in H20, placed nose down into deep cassettes for 
paraffin embedding, and 10[tm sections were cut from -20'C chilled paraffin blocks (to 
obtain good sections) onto in situ PCR Glass slides (Perkin Elmer). Slides were dried 
overnight at room temperature, and de-waxed by successive immersion in 2 changes in 
xylene (Sigma), (10 minutes each), 2 changes in 100% ethanol followed by 2-3 rinses in 
distilled water and a final immersion in I OmM Citrate buffer pH6, heated in a microwave 
for 5 minutes. Slides were cooled for 2-3 minutes, washed 2-3 times in PBS and then 
immersed in acetone at -20C, for 10 minutes, followed by PBS. 
2.6.3 Sections of Cervical Lymph Node. 
Cervical lymph nodes (CLNs) from experimental and control mice were harvested from 
the neck, and stored on liquid nitrogen. In appearance they are small nodules of hardened 
tissue. Frozen CLNs were embedded in OCT (Electron Microscope Services), and 10ýtNl 
sections were cut onto poly-L-lysine (Sigma, UK) coated in situ PCR slides (Perkin 
Elmer). Before staining, slides were air dried, fixed, for 10 minutes in acetone at -20'C, 
and then air dried. Sections were washed in PBS, blocked with 4% normal rabbit serum 
(Vector laboratories) for I hour then stained with rabbit anti-GFP FITC (Sigma, UK) at 
1: 50 for I hour. Sections were washed with 4 changes of PBS, dried, covered with prolon 
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aqueous mount, and a glass coverslip, and then dried overnight in the dark. Fluorescence 
was examined using an immunofluorescence microscope (Photonic sciences, Nikon). 
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Chapter 3- Optimising plasmid DNA delivery with cytofectins 
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3.1 Introduction 
DNA vaccines encoding the antigens of interest exhibit several beneficial properties as 
compared to alternative vaccine delivery systems (ie recombinant subunit or viral 
vectors). These include the ease of antigenic manipulation (via 
insertions/deletions/mutations of DNA coding sequences), relative stability of plasmid 
DNA and ease of manufacture. Despite these clear benefits, there remain obstacles to 
overcome. Although DNA vaccines demonstrate efficacy in several murine models of 
infectious disease, they lack potency in human and non-human primates. Lack of efficacy 
relates in part to degradation of naked DNA in vivo by endonucleases and in part 
inefficient cellular uptake and escape from the endosome (Lechardeur et al. 1999) and 
poor expression in non dividing cells (Escriou et aL 200 1). 
There are a number of barriers, both extra- and intracellular, that needs to be overcome 
before plasmid DNA can transfect cells in vivo. The degradation of naked plasmid DNA 
due to the presence of endonucleases within the extracellular milieu is the primary barrier 
to transfection. Once within the cell the plasmid DNA needs to escape from the 
endosome into the cytosol, and then from the cytosol into the nucleus before the plasmid 
















Figure 3.1.1, Cellular barriers in gene transfer 
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Degradation in the endosome 
orne Fusion/Disruption 
Although viral vectors are still superior in their transfection efficiency (MacLachlan et al. 
1999), their application raises a number of safety concerns (Ilan et al. 1997; Rubanyi 
2001). These include possible reversion of the viral vector to a pathogenic form or 
recombination with wild type viruses and hence propagation of recombinant DNA in the 
environment. Further potential problems with viral delivery systems include the 
induction of dominant immunological responses to the viral vector as opposed to the 
transgene, and pre-immunity to the vector which greatly reduce efficacy (Roth et al. 
2002). Conversely plasmid DNA is replication defective, non-pathogenic and non- 
antigenic. Complexes of DNA and cationic lipids, termed lipoplexes, have been shown to 
act as highly effective alternatives for free DNA (FeIgner et al. 1994). The rationale 
behind cationic lipids is their ability to facilitate transfer of the heavily charged plasmid 
DNA into the cytosol. The lipids used to complex plasmid DNA consist of a positively 
charged lipid, these include dimyristyloxypropyl-3-dimethyl-hydroxyethyI ammonium 
(DMRIE) (San et al. 1993; Wheeler et al. 1996; Klavinskis et al. 1997) and (+/-)-N-(3- 
aminopropyl)-N, N-dimethyl-2,3-bis (dodecyloxy)-l-propanaminium bromide (GAP- 
DLRIE) (Stephan et al. 1996; Wheeler et al. 1996; Sankar et al. 2002) which bind to the 
negative charge of the phosphate plasmid DNA backbone. These are combined with a 
neutral lipid to allow fusion to the plasma membrane and escape from the endosome to 
the cytosol. 
it is believed that transfection activity increases when the chain length and degree of 
saturation of the hydrophobic alkyl or acyl chains decreases (FeIgner et al. 1994). These 
changes induce an increase in the fluidity of the cationic lipids. It is this 
fluidity. which 
77 
not only determines the final size of the complexes (Akao et al. 1996, Regelin et al. 
2000), but may also act to destabilise the cellular membranes, thus increasing the 
transfection efficiency (Koltover et al. 1998; Hirsch-Lerner and Barenholz 1999). 
Another key component in the formulation of the lipid is the inclusion of a helper lipid. 
The addition of this helper lipid can alter the fluidity of the complexes. When DNA is 
added to the lipid bilayers the relative fluidity is reduced (Regelin et al. 2000), but if the 
formulation is a mix of cationic/zwitterionic lipids, then the binding of DNA to the lipid 
only induces minor changes in the fluidity of the lipid. (Hirsch-Lemer and Barenholz 
1999; Regelin et al. 2000). Many studies have confirmed that higher transfection levels 
can be observed in lipoplexes containing cationic lipids with co-lipid combinations 
(FeIgner et al. 1994; Balasubramaniam et al. 1996; Ferrari et al. 200 1; Heyes et al. 2002). 
However, the addition of a zwitterionic lipid remains contentious since there has been a 
reported an induction of complex rigidity due to the inclusion of curtain zwitterionic 
lipids (Zuhorn and Hoekstra, 2002), thus careful consideration of the helper lipid used in 
the complex is required. An example of a helper lipid is dioleoyl- 
pho sphatidyethano lam ine (DOPE), this is a zwitterionic lipid that can help maintain the 
fluidity of the DNA bound lipid complex (Regelin et al. 2000), and stabilise the cationic 
lipid suspension, as cationic lipids repel each other (Zuidam and Barenholz 1998). 
When 
DOPE is complexed with DMRIE it has been reported to improve transfection 
efficiencies and allows increased doses of DNA to be delivered in vivo 
(San et al. 1993). 
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An important factor in transfection efficiency is the environment in which the plasmid 
DNA complexes with the cationic lipids. There are many factors which can effect the 
complexing; the size of the plasmid DNA and cationic lipid complex, the concentration 
of lipid and plasmid DNA at the time of mixing, the mixing rate, order of addition, ionic 
strength of the mixing buffer, and the cationic lipid/DNA charge ratio have all been 
shown to represent a minimal set of parameters that affects lipoplex characteristics. 
However, when the same reagents and same concentrations, but different formulation 
procedures are used the resulting thermodynamic and biological stability of lipoplexes 
may again differ greatly (Thierry et al. 1997; Ferrari et al. 200 1 ). Transfections in vitro 
also Present multiple variables; the transfection competence of the cell type used (Son et 
al. 2000), cell seeding density (Lascombe et al. 1996), the degree of transformation of the 
cells (Harrison et al. 1995) and the stage of cellular replication cycle (Pickering et al. 
1994). Culture condition related effects include the presence of serum in the transfection 
mixture (Hwang et al. 200 1), dilution of lipoplex suspension (Staggs et al. 1996), the 
time lipoplexes are incubated with the cells (Zabner et al. 1995), type and concentration 
of salts and other biornolecules present in the liposome-nucleic acid mixing medium 
(Wasan et al. 1999). 
Upon contact with the cell, the lipoplex is taken up through endocytosis, 
however, the 
actual binding to the cell membrane, has still to 
be elucidated. Reports indicate that 
clathrin-mediated endocytosis is required. This 
has been indicated by the observation that 
transfection is inhibited by cyclodextrin induced cholesterol removal and resolved upon 
cholesterol resupply. (Zuhorn et al. 
2002). Others have shown that a fusion event, 
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between the membrane and the lipid is required to induce endocytosis (Almofti et al. 
2003). However, though the majority of reports suggest that lipoplex uptake occurs via an 
endocytosis mediated pathway, there are also some reports that the lipoplexes can 
directly fuse with the membrane and hence deliver DNA directly into the cytoplasm 
(FeIgner et al. 1987; Pires et al. 1999). 
Once the plasmid has entered the cell, the next barrier is to escape the endosome. It is 
proposed at this stage, a fusion between the endosomal membrane and the lipoplex takes 
place, causing the DNA to be dissociated from the lipid and delivered to the cytosol. 
(Nakanishi and Noguchi 2001). The co-lipid DOPE has been attributed with the 
properties to facilitate membrane fusion and aid in the destabilisation of the 
plasmalemma or endosome (FeIgner et aL 1994). 
The final cellular barrier is the translocation of the plasmid across the nuclear pore. The 
exact method of uptake into the nucleus is, as yet, unknown. However, certain criteria are 
documented in other fields of study. For example, the import of large nucleic acids 
requires the association with proteins. This is potentially similar to the transport of 
adenoviral genomic DNA, which binds endogenous histones to be transported into the 
nucleus. (Trotman et al. 2001). Another hypothesis is that mitosis is required for plasmid 
DNA to gain access into the nucleus, based on the observation that there is a close 
correlation between the onset of transgene expression and mitosis in synchronised cell 
cultures. (Brunner et al. 2000; Escriou et al. 2001). Nuclear import may play an 
important role as the half-life of plasmid DNA in the cytosol is recorded to be 90 minutes 
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(Lechardeur et al. 1999). However, cell division is essential for efficient transgene 
expression (Escriou et al. 2001). Cells that have been arrested in the GI phase of the cell 
cycle with aphidicolin only poorly express micro injected DNA. Furthermore, only the 
cells that escaped GI arrest expressed the plasmid DNA efficiently (Mortimer et al. 1999; 
Escriou et aL 200 1). 
Lipid cytotoxicity is an important consideration in the design of a DNA-lipoplex based 
vaccine strategy. In cell culture, lipoplexes cause changes to cells, including cell 
shrinking, reduced number of mitotic events, and vacuolization of the cYtoplasm. 
(Lappalainen et aL 1994). The effects in vivo of cationic lipids at certain concentrations 
are likely to be equally as toxic. Positively charged lipoplexes have been noted to activate 
complement via the alternative pathway (Chonn et al. 199 1). Intratrachael administration 
of lipoplexes has shown that a significant quantity of plasmid DNA enters the nuclei after 
release from lipoplexes. These cells undergo cell death, and thus result in low levels of 
transgene expression. (Uyechi et al. 2001). While lipoplex associated cytotoxicity may be 
detrimental to the levels of transgene expression, necrosis or apoptosis of transfected 
cells may actually enhance the immune response to the transgene. Cell death is associated 
with induction of inflammatory responses and hence recruitment of DCs required to 
prime an immune response to the expressed transgene. 
In this current study, we examined the efficiency of plasmid DNA transfection of cell 
lines. We investigated the relative efficiency of in vitro transfection of multiple cell lines 
with plasmid DNA constructs, at different nucleotide: cytofectin molar ratios. 
An 
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optimised transfection protocol was derived from this in vitro study and applied to an in 
vivo investigation. The efficiency of plasmid DNA lipoplex transfection was evaluated 
when delivered via the intra-nasal route and the levels of transgene expression examined 
at both the cellular and tissue level. 
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3.2 Results 
3.2.1 Increasing the Molar ratio of Cytofectin: nucleotide, increases the transfection 
efficiency of 293T cells.. 
Cytofectins have been widely used to increase the efficiency of plasmid DNA 
transfection. A number of properties can be investigated to improve the transfection 
efficiency generated by the complexing of plasmid DNA to the cytofectins. The 
properties investigated were the effects of plasmid DNA to cytofectin ratio on the 
efficiency of transfection, by quantifying the production of the plasmid encoded reporter 
gene product. The lipids GAP-DMORIE: DpyPE and DMRIE: DOPE were complexed 
with plasmid DNA encoding the reporter gene Secreted Alkaline Phosphatase (SEAP), at 
a range of molar ratios (nucleotide: cytofectin). Plasmid DNA complexed with the 
cytofectin was added to HEK293T cells for 48 hours, and the supernatants were tested for 
the presence of SEAP. The results show a dose dependant increase in SEAP production 
(hence transfection efficiency) peaking at 0.25: 1 and 0.5: 1 (Figure 3.2.1 a). Similar results 
were observed using the intracellular reporter gene, Green Fluorescent protein (GFP) 
(Figure 3.2.1 b). However, a dip in transfection was observed at the highest ratio of 
cytofectin (0-5: 1). This result implies a toxicity at high cytofectin concentrations, which 
was not apparent using SEAP as a reporter system. 
83 
C) C) c) CD C: ) 0 C) 
C) C) CD C) C) CD 
C%4 C) co (0 qql 
N 
V- V- 
(slue; eu. jedns poloolsuej; 








r. o -a ", 3 
- lw u 0 fi 42. 
LO c lu < 
0 C: ) 1- 4.0 & 0 12.1 -c 4-4 
16. C Z 
0 




< 2 -Z: CD 4ý Jcj , r- . 




% ci .. rw u rq < ce 
CD cý 
0 5 Z CD 4 *d :. C Irý e r. ti CD u ns 4.0 










ce P-ý ýý -0 u 
(A E l»4 
m = Z 1) u 
CD 
3m li -0 rA 
m a. iý CD.. u rý ý4-i ci 
9 
cc u 








l CD U ) 00 





C) C) C) C) 0 C) C) CD C) 0 C) 
C) 0) 00 1ý- (D LO I- Ct) CN - 
T- 
siloo 
Bujsse. jdxG dAD 10 eBe4uO3JGd 
001 Vu 
ell 
01 'm . 0& 1., 
























































+. i rA 
C) 
ei C u ýlw u 
.m Q ci CD 









3.2.2 By changing the lipid that complexes the DNA, the in vitro transfection 
efficiencies of 293T cells with a plasmid encodint! SEAP, can be altered. 
Although a number of lipid formulations could be potentially used for lipoplex based 
transfection, efficiencies vary with the lipid species used. Three proprietary lipid 
formulations (DMRIE: DOPE, GAP-DMORIE: DpyPE and GAP-DLRIE) under 
development by Vical were available for in vivo evaluation. It was therefore important to 
determine which of the three formulations had the greatest transfection potential in vitro 
prior to in vivo investigation. This was achieved by complexing a plasmid encoding the 
reporter SEAP, with each of the cytofectins at a cytofectin: nucleotides (DNA) molar ratio 
of 0.25: 1,0.13: 1 and 0.06: 1. The lipoplexes were then transfected into HEK293 cells for 
48 hours and the supernatants assayed for SEAP activity. At a ratio of 0.25: 1 both GAP- 
DMORIE: DpyPE and DMRIE: DOPE transfected the cells at a higher efficiency than 
GAP-DLRIE. However, GAP-DLRIE was efficient at the lower concentrations and as 
compared to naked DNA alone (Figure 3.2.2). On the basis of this result, 
GAP-DLRIE 
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3.2.3 Stabilily of the cytofectin is paramount to the efficiency of transfection of 
HEK293T cells. 
There are many issues to consider when choosing cytofectins for a vaccine strategy, one 
of these is the stability of storage. The effect of freeze-thawing upon the transfection 
efficiencies of these lipids was also investigated. GAP-DMORIE: DpyPE and 
DMRIE: DOPE were aliquoted and half the aliquots frozen at -20'C. The aliquots were 
then thawed and complexed, along with non-freeze thawed aliquots, with the SEAP 
encoded plasmid at the molar ratios of 0.25: 1,0.13: 1 and 0.06: 1 (cytofectin: nucleotide 
DNA). The resultant lipoplexes were then transfected into HEK293 cells and the 
supematants were assayed for SEAP activity after 48 hours of culture. The results show 
that GAP-DMORIE: DpyPE was unaffected by the freeze-thaw but the efficiency of 
DMRIE: DOPE was significantly reduced at the 4: 1 ratio (p=0.0004 using a paired 
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3.2.4 The effect of Cytofectin: nucleotide ratio on the transient transfection efficiency 
in NIH3T3 and HEK293T cell lines. 
Each cell line has a different potential for transfection, therefore just investigating one 
cell line is unrepresentative. To examine the transfection efficiency of DMRIE: DOPE 
between cell lines, the murine fibroblast cell line NlH3T3 was compared to the human 
embryonic kidney cell line HEK293. Plasmid DNA was complexed at the 
cytofectin: nucleotide (DNA) molar ratios of 0.5: 1 and 0.17: 1 and added to either the 
NIH3T3 or HEK293T cells. The supernatants were assayed for SEAP activity after 48 
hours in culture and clearly indicated that the cell line NlH3T3 was transfected at a low 
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3.2.5 The affect on SEAP production by different plasmid constructs. 
There is a great variety in plasmid design, from differences in the promoter sequence, to 
sequence variation within the plasmid DNA backbone. Changes in the basic plasmid may 
affect both the transfection and the transcriptional efficiencies of the plasmid DNA. It 
was therefore important to determine from the large range of commercially available 
plasmids, the most efficient plasmid for transfection. To achieve this, the transfection 
efficiencies of the plasmids VR (from Vical Inc), gWiz (from Gene Therapy Systems), 
and pCI (from Invitrogen) were investigated. The plasmids were complexed with the 
same lipid at the cytofectin: nucleotide (DNA) molar ratio of 0.25: 1 and transfected into 
HEK293 cells as previously described. The resultant SEAP production show that the VR 
and gWiz vectors transfect HEK293T cells to a comparable level, which is greater than 
those transfected with the pCI vector (Figure 3.2.5). Similar results were also obtained for 
plasmids encoding the HIV Gag protein. The plasmids VR, gWiz, pcDNA (Invitrogen), 
and pTRE-Shuttle (Clontech -a plasmid used in the generation of a recombinant 
adenovirus vector) were transfected into HEK293 cells as previously described. After 48 
hours post transfection, Gag protein was stained intracellularly, and the transfection 
efficiencies were compared for the different plasmids based on the amount of 
intracellular Gag observed. The result shows pTRE-Shuttle and pcDNA plasmids 
transfected at approximately 60% of the efficiency of the gWiz and VR plasmids. (Figure 
3.2.5b). 
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3.2.6 Investigation of the effect of DNA dose and relative DNA to cytofectin ratios on 
the transfection efficiency within the NALT followins! intranasal inoculation. 
The in vitro data that was generated in this study, defined the complexing conditions of 
plasmid DNA with cytofectins that optimised the transfection of cell lines. Using these 
principles, the transfection of NALT with plasmid DNA was investigated. The VR 
plasmid DNA encoding the reporter gene firefly luciferase was inoculated into the nares 
of balb/c mice. The plasmid DNA was complexed with the cytofectin DMRIE: DOPE 
either by altering the molar ratios (0.25: 1,0.13: 1 or 0.06: 1 cytofectin: nucleotide) or by 
altering the amount of plasmid DNA present (40[tg, 60ýtg or 80[tg) at the molar: molar 
ratio 0.13: 1. After 72 hours the NALTs were extracted and examined for the presence of 
luciferase. The results show that at 40pg, no transfection was observed in any of the 
complexed ratios. However, when the range of plasmid DNA concentrations were 
examined luciferase was found maximally at the 60[tg dose, with a reduction observed at 
80[tg. Transfection at 40ug was negligible. Each group was the mean of 4 mice, with the 
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3.2.7 Intranasal immunisation with a DMRIE: DOPE complexed GFP expressing 
plasmid, shows GFP expression within NALT 48 hours post immunisation. 
The previous experiment established that NALT tissue can be transfected with plasmid 
DNA. To examine which cells were transfected, 100ýtg of gWiz encoding GFP or control 
plasmid were complexed with DMRIE: DOPE at 0.17: 1 molar ratio (cytofectin: 
nucleotide) and administered intranasally to Balb/c mice. The nasal area of the inoculated 
mice were dissected, fixed in 4% formalin and decalcified. Paraffin sections were then 
cut and the GFP signal boosted via staining with an anti-GFP (FITC) poly-clonal 
antibody. The sections were then stained with the fluorescent DNA collating dye DAPI 
and examined by UV microscoPy. GFP staining was observed in cells surrounding the 
seromucosus glands, derived from mice administered with the GFP expressing plasmid, 
(Figure 3.2.7 - panels A and Q. No GFP was detected 
from sections derived from 
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3.2.8 Transgene positive dendritic cells can be detected locally and in the drainini! 
lymph nodes of mice following intranasal immunisation with GFP encodinj! 
lipoplex. 
Although transgene expression in vivo is important to establish for an effective vaccine, 
only transgene presentation by DCs can achieve priming of the immune system. It was 
therefore important to establish that intranasal inoculation of the DNA resulted in DCs 
containing the transgene product. To address this point, 100ýtg of gWiz expressing GFP 
or control plasmid, was inoculated intranasally into mice as described in the previous 
experiment. Mice were sampled at 48 and 72 hours post inoculation, NALT and CLN 
were removed by dissection. 
Due to small numbers of DCs within the NALT, it was impractical to examine sections of 
NALT for GFP positive DCs. To circumvent this problem, a single cell suspension was 
made from the pooled NALT within each group, and stained for the DC marker CD IIc 
with a PE-Cy5 labelled mAb. The DCs were then sorted by flow cytometry and dried 
onto a glass slide to form a cytosmear. The cells were then acetone fixed, the GFP signal 
boosted with an anti-GFP FITC conjugated polyclonal antibody and examined by 
deconvoluting UV microscopy. Approximately 60% of the DCs sorted from the gWiz 
inoculated mice were observed to be GFP positive where as the DCs 
from the control 
mice were all GFP negative (Figure 3.2.8). The deconvaluted 
image clearly shows the 
GFP to be contained within the cytoplasm, whereas the CD IIc staining only on the cel I 
surface. 
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Frozen sections were taken of the CLN of the inoculated mice from both 48 and 72 hours. 
The sections were acetone fixed, and stained for CD IIc and GFP as before and examined 
by UV microscopy. After 48 hours GFP positive DCs were not observed in either group 
(data not shown). However, by 72 hours GFP/CD IIc double positive cells could clearly 
be seen in the mice inoculated with gWiz-GFP (Figure 3.2.8). These results clearly 
indicates the presence of transgene positive DCs both locally at the site of inoculation by 
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For DNA vaccines to realise their full potential and translate to the clinic. will require the 
development of efficient delivery systems to enhance the level of plasmid encoded 
antigen produced. Possible approaches to overcome this hurdle include improving the 
plasmid by enhancing the promoter (Barnhart et al. 1998) or the use of cationic lipids 
(FeIgner et al. 1994). This study examined the potential of improving the transfection 
efficiency of plasmid DNA by increasing the production of the transgene both in vitro 
and then in vivo. Conditions for cytofectin complexing of plasmid DNA were examined 
in vitro and the resulting optimal conditions were investigated in vivo to examine the 
level of transfection and which cells were transfected. 
The study initially examined the effects of reducing the concentration of cytofectin upon 
the levels of transgene production within transfected cells. HEK293 cells that were 
transfected with a SEAP encoded plasmid, resulted in the accumulation of SEAP within 
the supernatants. When this plasmid was complexed with lowering concentration of the 
cytofectin DNIRIEDOPE, the amount of SEAP produced by the cells was decreased. The 
two highest concentrations of the cytofectin produced similar levels of SEAP (Figure 
3.2.1 a). However when intracellular reporter, GFP, and not a secreted reporter, SEAP, 
differences could be observed at the higher concentrations (Figure 3.2.1 b), with less GFP 
being present at the 2: 1 ratio than at the 4: 1 ratio (molar: molar plasmid 
DNA: cytofectin 
ratios). This phenomenon could be explained 
by the toxicity generated by the cytofectin. 
Toxicity generated by the cytofectins has been well documented (Chonn et al. 1991; 
Lappalainen et al. 1994, Nita et al. 1996), and cell death upon transfection has also been 
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recorded (Uyechi et al. 2001). With SEAP being a secreted reporter, cell death of 
transfected cells will result in the SEAP being leaked into the supernatant, hence the 
amount of transgene product observed at the 2: 1 ratio Cell death of the plasmid encoded 
GFP transfected cells results in the GFP being leaked away into the supernatant, reducing 
the number of GFP positive cells. 
To examine the optimal transfection efficiency of plasmid DNA within a cell line, three 
cytofectins were investigated. The cytofectins examined where DNIRIE: DOPE which is a 
1: 1 mixture of N-[ I -(2,3-dimyristyloxy)propyl]-N, N-dimethyl-N-(2- 
hydroxyethyl)ammoniurn bromide (DMRIE) and dioleoyl phosphatidylethanolamine 
(DOPE), GAP: DLRIE which is ((±)-N-(3-Aminopropyl)-N, N-dimethyl-2,3- 
bis(dodecyloxy)-l-propanaminuim bromide) and GAP-DMORIE: DpyPE which is 
composed of (±)-N-(3-aminopropyl)-N, N-dimethyl-2,3-bis(cis-9-tetradecenyloxy)-l- 
propanaminium bromide (GAP-DMORIE), and the co-lipid 1,2-diphytanoyl-sn-glycero- 
3-phosphoethanolarnine (DPyPE). The production of the transgene in cells transfected 
with the GAP: DLRIE complex plasmid DNA (Figure 3.2.2) was lower than those 
transfected with either the DMRIE: DOPE or the GAP-DMORIE: DpyPE. GAP: DLRIE is 
the only cytofectin tested that did not also contain a co-lipid, which 
for DMRIE: DOPE is 
DOPE, and for GAP-DMORIE: DpyPE is DPyPE. Similar to the results observed, the 
presence of a co-lipid has been documented to 
increase the transfection efficiency of 
plasmid DNA delivery (FeIgner et al. 
1994; Balasubramaniam et al. 1996; Ferrari et al. 
200 1; Heyes et aL 2002). 
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To examine if the conditions of the comPlexing of cytofectin to plasmid could be related 
to other cell lines, the cell line NIH3T3, a mouse fibroblast cell line, was transfected with 
SEAP encoded plasmid complexed with DMRIE: DOPE. Although transfection was 
observed the level of transgene production in NlH3T3 cells was reduced compared to the 
HEK293 cells (Figure 3.2.3). It has been reported that the composition of lipid bilayers 
may effect the uptake of the lipoplex (Ferrari et al. 2002), considering the difference 
between the lipid composition of a murine cell line and a human cell line, this could 
account for the differences in observed transfection efficiencies. 
Another key component to plasmid transfection is the plasmid itself, a lot of commercial 
development has been geared towards increasing the efficiency of the CMV promoter, 
thereby increasing the duration and magnitude of the encoded antigen production. In 
trying to improve the efficiency of a plasmid vaccine, the right vector has to be chosen, 
and the efficiency of the CMV taken into account. By examining the transfection 
efficiencies of different plasmids, there is a clear distinction between the different 
plasmid backbones and promoters (figure 3.2.5a and figure 3.2.5b). However, the main 
point of contention here is that standardisation between preparations of DNA. If one 
plasmid preparation has a slightly lower optical density at 260nm versus 280nm, or 
higher LPS content, or hasn't completely dissolved homogeneously, the dynamics of 
cytofectin complexing can be altered and the transfection efficiencies effected. 
Work is 
taken to ensure that the DNA samples are of equivalent standard, with purification being 
done by Caesium chloride, the DNA ratios all correlating to around 1.8. and 80% of the 
plasmid being supercoiled. 
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Once the in vitro properties were investigated, the question became can these trends be 
translated into an in vivo situation. There are many considerations to be taken into 
account when going in vivo, especially when designing a vaccine strategy. The 
development of non-needle, patient compliant, vaccine strategies are being investigated 
for their applications in third world countries. These strategies include immunisation 
using the following routes, intranasal, oral, rectal, and with powder jet technology, 
intradermal. Previous publications, has shown the efficacy of intranasal immunisation in 
eliciting a humoral and cellular response (Gao et al. 1997), not only within the mucosa 
but also within the systemic compartment of the immune system (Klavinskis et aL 1997). 
In all in vivo work, strict guidelines are in place set by the Home Office, one of these 
guidelines limits the amount of inoculum that can be given intranasally. With a very 
limited dose, a delicate balance must be observed, between the amount of plasmid 
possible to fit into the volume, and the amount of lipid that can be complexed to it. As the 
concentration of the lipid and the plasmid increases, the amount of particulate precipitate 
increases, limiting cellular uptake thus transfection efficiency (Solodin et aL 1995). There 
are other problems with his method of immunisation, which is the dropwise addition of 
the inoculurn. onto the nares, resulting in the mouse sniffing the inoculum into its nasal 
passages and transfecting the nasal epithelium. If the application of the inoculum 
is too 
rapid, then the mouse either swallows it, or sneezes it out, making 
it difficult to regulate 
the exact amount that is absorbed by the nasal passages. The 
data shows a threshold of 
amount of plasmid is required for detectable 
levels of transfection (figure 3.2.8), which is 
not effected by the amount of lipid present. 
However. at a set ratio, the amount of 
plasmid that can be complexed with the 
lipid for an optimal transfection seems to cover a 
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limited range. The reasons for this could be purely mechanical. As discussed, at high 
lipid to DNA concentrations, the amount of precipitate increases, thus lowering the 
transfection efficiency. At the lower lipid concentrations, as all the volumes for 
immunisation were kept the same, the concentration of DNA being added per application, 
is insufficient to cause optimal transfection. After a limited number of applications of the 
inoculum to the nares, future applications become less effective as the nasal passages are 
coated. The optimal dosage is delivered in the first few doses. Thus requiring a balance 
between increasing the plasmid concentration, the lipid concentration, and the volume 
required for immunisation. 
With the encoded antigen being found in the NALT 48 hours post immunisation (Figure 
3.2.7), the ideal cellular target required for plasmid DNA is the DC. In vitro studies have 
highlighted the difficulties of transfecting DCs with plasmid DNA, with only a few 
reports claiming success (Yang et al. 1999; Denis-Mize et al. 2000). This leads to the 
question of why the DCs in the NALTs are so heavily bearing GFP expression. The 
answer is either the DCs are being directly transfected, which is unlikely due to the in 
vitro evidence, or that they are being cross-primed (Corr et al. 1999), and are taking up 
the GFP that has been released from dead or dying cells, or that was in cells the DCs have 
phagocytosed. This leads to an interesting question, if the DCs are being cross primed, by 
the contents of dead or dying cells, by increasing the toxicity of a vaccine, will you boost 
the efficacy of a vaccine? This certainly seems to be confirmed when co-immunisation 
with DNA vaccines which express Fas or a mutated version of a caspase gene which 
induce the creation of apoptotic bodies has been reported to enhance cell mediated 
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immunity (Chattergoon et al. 2000; Sasaki et al. 2001). Whatever the mechanism, the 
DCs do appear to contain the GFP with over 70% of total NALT DCs as determined by 
the CD IIc expression containing GFP (Figure 3.2.9), and that cells expressing both GFP 
and CD IIc can be found within the draining lymph node 48 hours post transfection 
(Figure 3.2.8). 
To create a vaccine candidate for plasmid DNA, a number of conditions need to be 
investigated, 1) manufacture of the plasmid and the lipid, taking care to remove any 
impurities, and being able to store them, 2) optimising the expression of the plasmid 
promoter region, 3) optimisation of the ratios for the cell type that is being targeted, 4) 
transgene expression occurs, and manages to accumulate within the dendritic cells, 5) 
stability of transfection, the transgene being present for a length of time, 6) some 
adjuvant activity, for example CpG present on the plasmid, or adjuvanticity of the 
cytofectins. Although we have not touched upon parts 5 and 6, we have shown the 
importance of choosing the right plasmid, of optimising the ratio, and the effect of 
inappropriate storage of these materials. We have also shown, that in 
intranasal 
immunisation, the transgene product can be found within DCs 48 hours post inoculation. 
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Depending upon the route of immunisation with plasmid DNA, the level of transgene 
expression has been observed to alter radically. For example, if the route is intranasal 
(Gao et al. 1997; Okada et al. 1997), intravenous (Shichiri et al. 2003) or intraperitoneal 
(Lee et al. 2002), the naked DNA is rapidly degraded before it can transfect the tissues. 
In rat sera, plasmid DNA was shown to be degraded within 5 minutes (Yu et aL 2001), 
thus some method to protect DNA from endonuclease degradation and ability to facilitate 
uptake into cells is required. Chapter 3 discussed the role of cytofectins in plasmid DNA 
complexes and their ability to increase transfection. However, there were two main 
disadvantages to this method of transfection, 1) the low level of transfection in non- 
dividing cells, and 2) potential toxicity of the lipid to the cell. Novel methods of 
transfection have been investigated to overcome these problems and one of these methods 
is the use of cell penetrating peptides. 
Peptides have been developed to condense plasmid DNA and to target receptors, with the 
aim of delivering plasmid DNA to the cytosol via an endosomal pathway. The integrin 
binding domain of the american Pit viper snake venom fused to a 16 poly-l-lysine chain 
has been reported to condense and package the plasmid DNA (Collins et aL 2000). The 
binding of this peptide to the integrin receptor, induces internalisation of the receptor, and 
targeting to the endosome. However, the limitation for this delivery peptide system is that 
some mechanism to escape the endosome is required, 
for optimal transfection to occur. 
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Cell penetrating peptides have recently been discovered based on the observations that 
the proteins, HIV tat (Han et al. 2001), Antennapedia homeoprotein from Drosophila 
(Derossi et al. 1996) and VP22 of Herpes Simplex Virus type I (Elliott and O'Hare 2000) 
could translocate across the cell membrane into the cytosol of cells. These transduction 
properties were further defined to a small peptide element within the proteins, that 
contain basic amino acids (arginine and lysine), which are hypothesised to be important 
for lipid interactions and/or penetration of the membrane (Schwarze and Dowdy 2000). 
Peptides synthesised to contain these sequences, have also been reported to demonstrate 
translocational properties in vitro (Derossi et al. 1994; Derossi et al. 1996). For example, 
a 16 amino acid sequence, RQIKIWFQNRRMKWKK, comprising of the third alpha 
helix of the homedomain of Antennapedia, has been shown to be internalised in several 
cell lines (Mi et aL 2000). The properties of these peptides have been examined by fusing 
the translocation sequence to the sequence of a reporter peptide or protein. One study 
used P-galactosidase as a reporter, and examined the distribution of the Tat-fused reporter 
protein following intraperitoneal injection (Fawell et al. 1994). This study demonstrated 
high levels of P-galactosidase activity, in heart, liver and spleen, with low to moderate 
activity observed in lungs and skeletal muscle. 
The exact mechanism of translocation is unknown, current hypotheses suggest that the 
high positive charge of these peptides, facilitates binding to the negative charge of the 
lipid bilayer of the cell (Drin et aL 2001). An initial binding of these complexes to 
heparin sulphate has been suggested, similar to the uptake of cationic lipids (Suzuki et al. 
2002). Following initial binding, translocation of the peptide across the cell membrane is 
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not clearly understood. It has been hypothesised that these peptides forms a reverse 
micelle that transverses through the membrane and into the cytosol (Berlose et aL 1996). 
This translocational property has been mapped to the tryptophan at position 6, and a 
substitution of that amino acid, can abrogate the translocational properties of the peptide 
(Berlose et aL 1996). It has also been reported that transfection with these peptides can 
occur in an ATP independent manner. At 4'C transfection can occur, suggestive of 
traversing the cell membrane in a metabolic independent manner. However, other studies 
comparing uptake at 4'C and 37'C, suggest that both an endocytic as well as a 
translocation uptake mechanism may operate (Dom et aL 2003). The amphipathic 
conformation of the Antennapedia peptide is considered a critical component of its 
translocation activity. A simple mutation of one of the amino acids that change this 
composition, abrogates much of its ability to translocate across the membrane (Dom et al. 
2003). 
There have been recent reports suggesting that the uptake of these peptides is artifactual, 
and that the highly basic nature recruits the peptides to the nucleus upon vigorous 
washing or even very mild fixation procedures of the samples (Richard et al. 2003). 
Thus, when examining fluorescently labelled peptide, or fusion proteins, the fixation 
process ruptures the membranes. This allows the peptides to gain entry, and traffic to the 
nucleus, due to the electrostatic attraction of the highly negatively charged DNA within 
the nucleus. Other published reports refute these observations. Firstly, the Antennapedia 
peptide has been reported to be present in the cytosol during live cell confocal 
microscopy. The peptide has also been documented to increase transfection efficiency of 
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adenoviral particles (Gratton et al. 2003). Also conjugation of the tat translocation 
peptide with plasmid DNA has been reported to enhance cellular transfection in vitro and 
in vivo (Torchifin et al. 2003). 
Work reported in the present chapter investigated the efficiency of Antennapedia 
complexed DNA into transfected cells in vitro and compared them to the cationic lipid, 
GAP-DMORIE: DpyPE, and the Polymolossin peptide. We show that the Antennapedia 
peptide does transfect cell lines; however, the transfection is very variable, depending on 
batch to batch variation, as well, as requiring a number of conditions to efficiently 
transfecting the cells. 
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4.2 Results 
4.2.1 Investigation of the comparative efficiency of cytofectin and peptide mediated 
DNA transfection in vitro. 
Plasmid DNA alone is relatively inefficient at cell transfection. Numerous methods have 
been investigated including use of cytofectins and synthetic peptides. In this study, a 
peptide derived from the Antennapedia protein was investigated to determine the 
efficiency of cellular transfection relative to other transfection methods using the plasmid 
gWiz encoding SEAP as a reporter protein. In all cases, the amount of DNA was kept 
constant at I [ig and the amount of peptide/cytofectin varied. The effect of the cytofectins, 
GAP-DMORIE: DpyPE (complexed at 0.5: 1,0.25: 1 and 0.13: 1 cytofectin: nucleotide 
molar ratio) and Lipofectamine (1: 05,1: 1, and 1: 2 (w/w)), were compared to the peptides 
polylysine-molossin, and Antennapedia. Transfection ratios were calculated based on the 
optimal ratios derived from the literature or earlier work on the cationic lipids reported in 
Chapter 3. Since poly-molossin is an integrin binding protein, the complexed DNA 
requires some method to escape the endosome. To facilitate endosomal escape, 
chloroquin was incorporated into the transfection formulation at 25[tM, 50ýtkl, or 100[tM 
with DNA: peptide (w/w) at 1: 3. For comparison lipofectamine was incorporated as an 
endosomal escape agent at a plasmid DNA: peptide: lipofectamine formulation of 1: 3: 05, 
1: 3: 1,1: 3: 2 (w/w/w). The Antennapedia peptide was tested at the nucleotide: peptide 
ratios 0-1: 1,0.05: 1 and 0.03: 1, to initially examine its transfection efficiency. Although 
cationic lipids demonstrate greater transfection efficiency, the Antennapedia peptide also 
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transfect the HEK293T cells, to the same efficiency as the polylysine-molossin peptide 
with chloroquin (Figure 4.2.1). 
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4.2.2 Optimising the transfection efriciencies of peptide based deliveEy systems. 
To maximise the efficiency of transfection with a peptide based delivery system, the 
peptides Antennapedia (Antp), polylysine-molossin and polylysine-antennapedia (Antp- 
K16) were each examined at a range of molar: molar ratios of DNA: peptide, to determine 
the oPtimal ratio for transfection. The ratios examined were 2.5: 1ý1: 1,0.4: 1,0.2: 1 and 
0.1: 1 at a molar ratio of peptide: nucleotide (DNA). The maximal transfection efficiency, 
for Antp-K 16 peptide it was between the ratios 0.5: 1 and 0.2: 1, for the Antp it was at 1: 1, 
and for polylysine-molossin it was 2.5: 1. Each of the peptides induced an increase in 
reporter gene expression of between 7.1 and 7.5 fold against DNA alone at the maximal 
transfection efficiency (Figure 4.2.2). For the Antp-K16 peptide, it was observed that 
maximal transfection was achieved at a higher ratio of nucleotide: peptide, indicating that 






clý ci ci ci 
o 0 0 0 
C) C) C) C) C) C) C) 0 C) 
C) C) C) C) CD CD C) 0 
LO C) LO 0 U') CD U') CD 
qq 'IT m (Y) C%4 T- Ir- 
(slueleu. jadns 
uolloolsue. il lw/Bu) pe: )npoid dV3S 
-0 w Q) 
u U Z 
Q) (U m 
c) 
- 0 < 
ý4 45 
(U -0 Q) O u 1- "V L -4-0 X 




Z -0 = C (c; 
ei CJ -ZD 
0 
,0 cn 75 r- u 
+ > C i -. 
0 u 
. 
w :i u * 
4 1 
2 
CC oo - -- CZ . i 
4.0 le 
*- 
ci CD. - 6 Pi c) 2 - i i CD. ce - - Q M -e Ci, 
ZZ 
u E Z ý, ýi-a u cn - 
cý 0 -4- 
, 




ýý < -0 
118 
4.2.3 Investigating the effect of freeze thawing on the transfection efriciency of Antp- 
K16. 
One of the most critical parameters to achieve transfection efficiency is the structural 
composition of transduction peptides (Fischer et al. 2000). If the structure is disrupted or 
changed, these may lower the transfection efficiency. One mechanism by which this can 
occur is by freeze thawing. We therefore tested the Antp-K16 peptide, after it had 
undergone a cycle of freeze thawing, for its ability to transfect HEK293T cells. The 
Antp-K16 was split into two aliquots, one aliquot underwent a freeze thawing cycle at 
-201C. The peptides were complexed with a plasmid encoding SEAP at the 
cytofectin: nucleotide molar ratios 2.5: 1,1: 1,0.4: 1,0.2: 1 and 0.1: 1 and applied to 
14EK293 cells. After 48 hours, the supernatants were harvested and investigated for the 
presence of SEAP. The transfection efficiency is much reduced upon freeze thawing, 
although similar levels of transfection occur at the 2.5: 1 ratio, with a 2.8 fold increase 
above DNA alone. (Figure 4.2.3) Since, the amount of peptide is reduced, the transfection 
efficiency of the non-freeze thawed Antp-K16 increases, as opposed to the efficiency of 
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4.2.4 Comparison between Antp-Kl6 and Antp peptides. 
Poly-L-lysine has been shown to condense DNA, and protect it from degradation. An 
Antennapedia peptide was synthesised with 16 lysine residues fused to the carboxy 
terminus, to act as a carrier of the DNA (Antp-K16). However, since the Antennapedia 
peptide is highly charged, it is possible that it may act as a carrier without the added poly- 
L-lysine. Similarly, it is possible that the poly-L-lysine could in some way destabilise the 
DNA-peptide complex. To investigate these issues, HEK293T cells were transfected with 
either the Antp-K 16 or the Antp peptide, at the ratios of 2.5: 1,1: 1,0.4: 1,0.2: 1 and 0.1 :I 
cytofectin: nucleotide (molar ratios) using the gWiz-SEAP plasmid. Peak expression of 
secreted SEAP for the Antp-K16 complexed plasmid was observed between 0-2: 1 and 
0.4: 1 ratios, however a greater concentration of Antp peptide was required for the peak 
SEAP expression which was observed at the 1: 1 molar ratio (Figure 4.2.4). By including 
chloroquin in the transfection, we observed that the amount of SEAP protein produced by 
the Antp, complexed DNA in the presence of chloroquin peaked at the same concentration 
as the Antp-K16 complexed plasmid DNA, at a ratio of 0.25: 1 (Figure 4.2-5). The same 
concentrations of the Antp-K16 peptide complexed with plasmid DNA was observed to 
induce peak levels of SEAP production in the presence or absence of chloroquin at the 
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4.2.5 Transfection with Antennapedia peptide and a GFP expressing 121asmid. 
A second plasmid encoded reporter, GFP was used to investigate enhancement of 
reporter protein expression by the Antp peptide delivery system. HEK293 cells were 
transfected with a GFP expressing plasmid, gWiz-GFP, at the peptide: nucleotide (DNA) 
molar ratios of 2: 1,1: 1,0.5: 1,0.25: 1,0.17: 1,0.13: 1 and 0.1: 1. After 48 hours, the cells 
were analysed for GFP expression by flow cy-tometry. The levels of transfection 
observed, over a range of peptide: nucleotide ratios (Figure 4.2.6) demonstrated the same 
pattern observed with the SEAP encoded plasmid (Figure 4.2.4 and 4.2.5). Optimal 
transfection was observed at the ratios of 0.17: 1 and 0.25: 1, with over 80% of all cells in 
the culture expressing the GFP transgene. Over 25% of cells at a 0.17: 1 
peptide: nucleotide ratio expressed GFP with a mean fluorescent intensity greater than 
600 indicative of high level of GFP expression, which may relate to transfection of each 
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4.2.6 Investigating the Transfection efficiencies of a new batch of Antp-K16 peptide. 
To further investigate the properties of this peptide, a new batch had to be synthesised by 
Cambridge Research Biochemicals, the same company who initially synthesised the 
peptide. To examine if the transfection efficiencies generated by the new batch was 
comparable to previous transfection, HEK293 T cells were transfected with Antp 
complexed DNA at the ratios 4: 1,2: 1,1: 1,0.5: 1,0.25: 1,0.17: 1,0.13: 1,0.1: 1,0.8: 1, and 
0.7: 1 peptide: nucleotide (DNA). The optimal transfection was observed at the 0.5: 1 ratio 
(Figure 4.2.7), compared to the optimal ratio previously observed to be between 0.17: 1 
and 0.25: 1 (Figure 4.2.4 and 4.2.6). However, the production of the SEAP reporter was 
also much reduced, with the maximal transfection being observed to be 32 fold less than 
the optimal transfection previously reported in Figure 4.2.4. 
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4.2.7 Chanp_inp_ the transfection formulation can affect the efficiency of transfection.. 
The conditions for complexing the peptide are crucial, for example the correct pH is 
required to allow for conformation and to maintain the correct charge. To try and 
improve the level of transfection observed in Figure 4.2.7, different buffers were 
investigate to formulate the DNA and peptide (at 0.17: 1 peptide: nucleotide ratio) was 
investigated. The effects of IOmM Tris, ImM HEPES, Saline and PBS were compared 
using the plasmid gWiz-SEAP, to evaluate SEAP protein . expression following delivery 
with GAP-DMORIE: DpyPE or DNA alone. The results show that the absolute level of 
transfection observed is reduced irrespective of delivery formulation compared to figures 
4.2.1 to 4.2.6 (Figure 4.2.8). However, it can be clearly observed that optimal transfection 
was achieved using Tris to buffer the complexing of Antp with DNA. The level of 
transgene observed was increased 5.4 fold above that observed with DNA alone, 
compared to a 3.6 fold increase observed using saline as buffer. Inclusion of PBS, only 
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4.2.8 Time course for optimal complexing of the Antennapedia-DNA complex. 
There have been reports in the literature that the Antennapedia peptide can bind very 
efficiently to plastic. In such a scenario, then the amount of Antennapedia peptide that is 
available for complexing may be significantly reduced. Therefore a time course was 
examined to address the efficiency of transfection, by changing the duration of time 
available for the peptide and DNA to complex. The time course ranged from immediate 
addition of the DNA and peptide to the target cells, or incubating the peptide and DNA 
complex for 5 to 30 minutes before addition to the cells, at the peptide: nucleotide (DNA) 
molar ratio of 0.17: 1 (figure 4.2.9). These complexing conditions were compared to DNA 
transfection with GAP-DMORIE: DpyPE, and DNA alone as controls. Although the 
amount of reporter protein is reduced with the new peptide batch compared to the GAP- 
DMORIE: DpyPE control, there is a noticeable loss 7.1 fold decrease in transfection 
efficiency, when the DNA and peptide are complexed for 5 mins prior to addition to the 
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There are two major problems inherent in plasmid DNA immunisation. These are: 1) 
protecting the DNA from degradation by serum or tissue endonucleases; and 2) efficiency 
of plasmid DNA internalisation by the target cell. A well documented procedure to 
overcome these problems is to complex the plasmid DNA with cytofectins. However, 
there are also problems with this method of transfection. There are potential 
disadvantages to the use of cytofectins since they have been observed to primarily 
transfect dividing cells, and they have also been attributed with varying degrees of 
cellular cytotoxicity. Consequently, a novel, non-toxic method of DNA delivery has been 
investigated that will equally target both dividing and non-dividing cells. This method 
involves the use of peptides derived from a class of proteins that can directly translocate 
across the plasma membrane, for example HIV-Tat protein or the Antennapedia 
homeoprotein from Drosophila. These peptides have been reported to cross the 
membrane of a cell and transfer directly into the cytoplasm, bypassing the endosome 
(Joliot et al. 1991; Joliot et al. 199 1; Bloch-Gailego et al. 1993; Le Roux et al. 1993). 
The incorporation of highly basic amino acid sequences from certain translocation 
peptides has been reported, with much of the early work investigating the translocation 
properties of the peptide. The ability of these peptides to cross the plasma membrane 
when fused to large macromolecules, gave rise to the idea of complexing the peptides 
with plasmid DNA. Although within the literature, very little work 
has examined the 
transgene product resulting from transfection with plasmid DNA complexed ývith the 
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Antp peptide, previous studies have reported an increase in the efficiency of Antp 
complexed viral particles (Gratton et al. 2003), and Antp complexed oligonucleotides 
(Dom et al. 2003). All point to the efficient movement of these large macromolecules 
into the cytosol, and even into the nucleus. The observed cellular entry of these peptides 
across the plasma membrane reported in the literature, gives credence to the data we have 
shown in this thesis, that not only can the translocation peptide enter the cytosol. but can 
also carry large plasmid DNA molecules, that will transcribe and translate the encoded 
transgene in the transfected cell. The Antennapedia peptide complexed to a GFP plasmid 
(figure 4.2.6) was shown to transfect 75% of the cells at the optimal ratio of transfection. 
Of those 25% demonstrate high levels of gene expression (MFI>400), indicative that the 
cell has either efficiently produced the transgene, or has been transfected with more than 
one copy of the plasmid. 
Recent studies by other investigators have examined the ability of the Tat peptide to carry 
plasmid DNA across the plasma membrane and transfect cells (Eguchi et al. 2001; 
Snyder and Dowdy 2001; Ignatovich et aL 2003). The results observed are very similar to 
the results observed within this study. The transduction peptides do increase the level of 
transgene produced compared to naked DNA, but the rate of transfection is reduced, 
compared to the transfections observed with the cationic lipids mediated gene 
delivery. 
Two Antennapedia peptides were investigated in this study; one of them only contained 
the 16 amino acids that induced translocation (Antp). However, the other contained 
16 
lysine residues (Antp-K16) to encapsulate the plasmid DNA. The presence of the 
lysine 
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induced lower the concentrations of Antp-K16 to transfect efficiently resulted in higher 
level of reporter gene production than the comparative concentration of the Antp peptide. 
(Figure 4.2.4). This is potential due to the lysine residues either facilitating uptake to the 
cell, or by protecting the plasmid DNA while it is escaping the endosome. The 
Antennapedia peptide is thought to bind to the cell membrane by charge related means 
(Drin et al. 2001), therefore it is unsurprising that the Antp-K16 which has a greater net 
positive charge would bind to the membrane stronger, and thus facilitate a greater uptake 
of the peptide. 
The Antp peptides have been reported to translocate to the cytosol in an endosome 
independent manner (Berlose et al. 1996), therefore upon addition of chloroquin an 
endosomal disruption agent, any DNA-peptide complex that is in the endosome will be 
released into the cytosol. Thus DNA entering directly into the endosome (via receptor 
mediated endocytosis) will be released into the cytosol, resulting in a significant increase 
in the level of reporter protein produced. In this study, Antp-K16 peptide complexed 
plasmid DNA transfected cells at a lower concentration than the Antp peptide 
in the 
absence of chloroquin (Figure 4.2.4). However, in the presence of chloroquin the 
concentration of Antp peptide and Antp-K16 required to optimally transfect cells with 
plasmid DNA was identical (Figure 4.2.5). This suggests that the complex 
is targeted to 
the endosome as has been recently reported (Koppelhus et al. 
2002; Richard et al. 2003) 
and the Antennapedia core peptide allows the plasmid 
DNA to escape from the endosome 
by an unknown mechanism. The presence of the poly-l-lysine protected 
the plasmid DNA 
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from degradation, thus lower concentrations of the Antp-K16 peptide facilitated 
transfection in the absence of an endosomal disruption agent. 
The work in this chapter has further demonstrated that secondary structure is critical for 
the transfection efficiency of Antp based peptides and is in agreement with earlier studies 
(Berlose et al. 1996). Freeze thawing of the peptide and suboptimal buffering (pH) of the 
complexing media was observed to reduce transfection efficiency. Both parameters 
directly affect the secondary structure of this highly basic protein. Although peptides are 
expensive to manufacture, the ability to transfect non-dividing cells is a beneficial 
attribute over lipid based cytofectins currently under investigation. Further studies into 
the properties of these peptides, especially with recent reports that the initial 
investigations into the transfection properties were artifactual (Richard et al. 2003) is 
essential. 
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Naked plasmid DNA has been shown to be efficacious in eliciting immune response 
within murine models. However, the quantity of DNA required for efficient primate 
vaccination is too large to be practical or financially viable. A possible approach is to 
increase the efficacy of plasmid DNA vaccination is the use of adjuvants. Examples of 
molecules that display adjuvant like activity include the chemokines, CCL5 (RANTES) 
(Kim et al. 2000; Sin et al. 2000; Oh et al. 2003), CCL3 (MIP- I cc) (Kim et al. 1998; Kim 
et al. 2000; Youssef et al. 2000). These molecules recruit DCs and monocytes in a 
concentration dependant manner. Alternatively, it may be possible to increase the total 
number of DCs in the local area of immunisation by the use of growth factors, for 
example GM-CSF (Iwasaki et al. 1997; Sin et al. 1998; Operschall et al. 1999). One 
major advantage of these protein adjuvants is that they can be encoded by the plasmid 
DNA vaccine itself and therefore co-delivered with antigen. 
In 1997, a novel CC chemokines, CCL20, was first identified using BLASTN and 
TBLAST searches against GENBANK using cDNA and protein sequences of chicken 
lymphotactin and other chemokines (Rossi et al. 1997). CCL20, also known as LARC 
(Liver and activation-regulated chemokine), Exodus-2 and MIP-3cc. The CCL20 gene 
was mapped to the D2SI59 chromosomal marker at chromosome 2q33-q37 by in situ 
hybridisation. Two clones encoding the entire human CCL20 gene were isolated from a 
yeast artificial chromosome (YAQ library (Hieshima et al. 1997). Sequence analysis 
showed a 20-28% homology between CCL20 and other CC chemokines family members. 
1)7 
CCL20 expression was demonstrated within lymph nodes, appendix, PBL, foetal liver, 
foetal lung (Hieshima et al. 1997; Rossi et al. 1997), and also shown to be upregulated at 
inflamed epithelial surfaces (Power et al. 1997) and by infected macrophages 
(Matikainen et al. 2000; Abiko et al. 2003) 
Analysis of the biological activity of CCL20 showed it was a potent chemoattractant for 
memory T cells, naive B cells, immature dendritic cells and Langerhan' cells. It was also 
shown to be weakly chernotactic for granulocytes. (Hieshima et al. 1997; Dieu et al. 
1998; Charbonnier et al. 1999; Liao et al. 1999; Brandes et al. 2000; Dieu-Nosjean et al. 
2000; Matsui et al. 200 1; Hosokawa et al. 2002). Therefore, it was suggested that CCL20 
represented a promising candidate as a genetically encoded adjuvant. 
Exposure of the murine monocytoid J774 cell line to lipopolysaccharide (LPS) induced 
the expression of CCL20. However, TNFa, IL- I P, IFN-y and IL-4 were unable to induce 
CCL20 expression in this cell line (Tanaka et al. 1999). In one study, CCL20 mRNA was 
shown to be present within intestinal tissues and upregulated upon treatment with LPS. 
This correlated with an increased production of CCL20 protein. (Tanaka et al. 1999). 
The specificity of CCL20 receptor binding was determined using a panel of stably 
transfected HEK293T cell lines, each of which expressed a single chemokine receptor 
family member. CCL20 was shown to be unable to bind to either CCRI-5 or CXCRI-2 
(Liao et al. 1997). This was taken as evidence that CCL20 bound to a unique chemokine 
receptor. The cognate receptor for CCL20, was identified as CCR6 (initially called 
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SRL22) (Greaves et al. 1997; Liao et al. 1997; Power et al. 1997). The CCR6 receptor 
was identified by RT-PCR, using degenerate oligonucleotide primers based on the 
sequence homology of known chemokine receptors, and was reported to be the specific 
receptor for CCL20 (Power et aL 1997). Out of a panel of 25 chemokines tested CCR6 
specifically bound CCL20. CCR6 showed differential expression on human dendritic 
cells. DCs derived from CD34+ cord blood precursors were CCR6+"' whilst DCs derived 
from human peripheral blood monocytes were CCR6-ve. (Greaves et al. 1997). 
Messenger RNA for murine CCR6 was also shown to present within B cells, CD8- 
splenic dendritic cells and CD4+ T cells when sorted by flow cytometric purified 
populations, and analysed by RT-PCR. (Varona et aL 1998). 
CCL20 is currently a member of a unique group of chemokines that are not promiscuous 
in their binding and are specific for a single receptor. CCL20 exhibits a similar structure 
to most chemokines, with a three-stranded beta-sheet and an overlying alpha-helix 
(Perez-Canadillas et aL 2001). The chemokines differ in the conformation of their N- 
terminal DCCL motif, which has been postulated to account for receptor specificity. As 
could the narrowness of the groove between the N-loop and the beta2-beta3 hairpin as 
compared to other chemokines (Perez-Canadillas et al. 2001). In support of this 
hypothesis, human beta defensin 2 (a non-chemokine molecule that can bind to CCR6), 
demonstrates similar structural features to CCL20 in the absence of any significant amino 
acid sequence homology (Yang et al. 1999; Biragyn et al. 2001; Perez-Canadillas et al. 
2001). 
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CCL20 is thought to play a role in the homeostasis of DC trafficking (Dieu-Nosjean et al. 
1999; Sozzani et al. 1999; Caux et al. 2002). Immature DCs express CCR6, which upon 
DC maturation, is lost and replaced with CCR7 (Dieu et al. 1998). In transwell migration 
assays, DCs derived from CD34+ hematopoietic progenitor cells (HPCs) or monocytes, 
expressed CCR6 and migrated to CCL20 in a concentration dependent fashion. If these 
DC cultures were stimulated with LPS, TNFa, or CD40L they downregulated their 
CCR6, and upregulated their CCR7 expression, and subsequently failed to migrate 
towards CCL20 (Dieu et al. 1998). 
Iwasaki and Kelsall, 2000 defined the DC populations present within the Peyer's patch 
and provided evidence that CCL20 has a functional role in DC homeostasis in vivo. They 
identified 3 subsets of DCs in the Peyer's patch; myeloid DCs (CD II c+ CD II b+), 
lymphoid DCs (CD II c+ CD8a+) and a third subset defined as CD II b- and CD8a-. 
Histological analysis of Peyer's Patches localised CCL20, CCR6 and the myeloid DCs to 
the subepithelial dome (SED). In contrast, lymphoid DCs localized to the T cell-rich 
inter-follicular region (IFR), which in turn correlated with the expression of CCR7 and its 
cognate chemokine CCL19 (Iwasaki and Kelsall 2000). 
This in vivo histological evidence supports the hypothesis that CCR6 ligands such as 
CCL20 may recruit immature DCs to the site of antigen exposure. This may in turn, 
result in an enhanced level of priming and therefore an enhanced immune response. 
Plasmid encoded CCL20 may therefore increase the efficacy of plasmid DNA vaccines 
by local expression at the site of immunisation. Further evidence to support this theory 
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came from studies of turnour immunotherapy. When injected into subcutaneous turnours, 
adenovirally expressed CCL20 led to the recruitment of DCs in vivo (Fushimi et al. 
2000). 
This study examines the potential of CCL20, expressed from a non-viral vector, as a 
genetic adjuvant. We show the cloning of CCL20, validation of its biological function, 
and have examined the capacity of plasmid encoded CCL20 to recruit DCs to the site of 
inoculation. (NALT) in vivo. In order to maximise expression from plasmids, the 
information derived from chapter 3, "Optimisation of DNA delivery using cytofectins" 
was utilised to enhance transfection efficiency in all the studies in this chapter. 
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5.2 Results 
5.2.1 Validation of CCR6 and CCL20 expression within NALT. 
Our strategy was based upon the expansion of priming through the recruitment of DC 
populations to the site of immunisation. It is essential that the adjuvants investigated are 
biologically active within the mucosa. Therefore, we investigated CCL20 and CCR6 
expression within NALT. NALT was harvested from mice and a 294 bp band (CCL20) 
and a 548 bp band (CCR6) mRNA was demonstrated to be present by RT-PCR (Figure 
5.2.1) RPRT and no reverse transcription controls showed that these bands were specific 
for CCL20 and CCR6 cDNA and not due to genomic DNA contamination. CCR6 protein 
was demonstrated to be present by flow cytometry in NALT using polyclonal rabbit a 
mouse CCR6. a kind gift from Christine Powers, Serono Pharmaceuticals, Switzerland 
(Figure 5.2.2). 
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5.2.2 Verification of CCL20 expression 
Murine CCL20 was cloned into the expression vector pcDNA3. I+ by Dr Patricia Novel I i. 
Murine CCL20 was identified using an EST clone, and inserted into the plasmid 
pcDNA3.1 between the EcoRV and the BamHl restriction enzyme sites (Figure 5.2.3). 
Once the sequence was confirmed the expression of the plasmid was examined in vitro. 
pcDNA3.1-CCL20 was complexed with DMRIE: DOPE at a cytofectin: nucleotide molar 
ratio of 0.17: 1 and applied to HEK293 cells. After 48 hours, the supernatants were 
harvested and separated on a 15% SDS-PAGE and assayed by Western blot for the 
presence of the protein. The western blot shows the presence of CCL20 using a rat 
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5.2.3 Verification of cloned CCL20 biological activity 
5.2.3.1 Calcium Flux Assay 
CCL20 has previously been shown to induce calcium flux in CCR6 positive cells (Baba 
et al. 1997). To confirm the biological activity of cloned CCL20, supernatants from 
HEK293T cells, transiently transfected for 48 hours with pcDNA3.1-CCL20 or 
recombinant rat CCL20, used to stimulate rat splenocytes in a calcium flux assay (with 
the aid of Dr James Peace, Imperial College). Rat splenocytes were harvested and T cells 
and B cells purified by passage of single cell suspension through nylon wool columns. 
200nM or 500nM of recombinant rat CCL20 or I OnM of SDF- I (x were used for positive 
controls of calcium flux (figure 5.2.7). From the experiments performed, rat splenocytes 
did not flux in response to CCL20, or the control chemokine SDF- I a. However, the Ca 2+ 
release assay was still valid, as the detergent Triton-80 results in a flux. To address this 
issue in a more specific manner, cell lines stably transfected with human and murine 
CCR6 were examined for calcium flux with recombinant human and murine CCL20 
respectively. Non-transfected HEK293T cells were used as a negative control (figure 
5.2.8). Upon addition of either the CCL20 obtained from transfected HEK293 cells, or 
recombinant CCL20 (arrows and labels), there was a small species specific calcium flux. 
However, the magnitude of the flux generated was not significantly above background to 
be considered positive. In a personal correspondence with Dr James Peace, cell lines can 
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5.2.3.2 Transmi2ration Assay 
5.2.3.2a Validation of CCR6 expression by bone marrow derived DCs. 
CCL20 was reported to promote migration of CCR6 positive cells in a concentration 
dependent manner (Charbonnier et al. 1999). In order to validate the capacity of bone 
marrow derived DCs to respond to CCL20 in a transmigration assay, CCR6 expression 
was confirmed by flow cytometry. Bone marrow derived dendritic cells (BMDCs) were 
cultured in the presence of GM-CSF, and examined by flow cytometry for CD11c (a 
murine DC cell marker), MHC class 11 and CCR6 expression. 59% of the gated 
population co-expressed CD II c+, MHC class ll+ and CCR6+ (Figure 5.2.9). 
5.2.3.2b Transwell migration assay. 
The chernotactic potential of recombinant and transfected CCL20 were determined by 
assessment of their respective capacity to cause CCR6+ BMDCs to migrate from the 
upper to the chemokine containing lower chamber in a transwell migration assay. The 
effects of a range of recombinant murine CCL20 concentrations and supernatants from 
HEK293T cells transfected with the CCL20 plasmid or supernatants from control 
transfected cell were compared for their capacity to induce migration. Cells that had 
migrated into the lower chamber or onto the lower side of the filter were counted after 4 
hours. The results showed that there was no significant difference between wells 
containing the chemokine CCL20 and control wells. Therefore, in this assay bone 
marrow derived dendritic cells do not migrate in a concentration dependent manner 
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5.2.3.3 CCL20 induced tyrosine phosphorylation. 
Another biological property of CCL20 is the induction of tyrosine phosphorylation upon 
CCR6 cross-linking. Recombinant CCL20 and supernatants from 48-hour 
pcDNA3.1-CCL20 transfected HEK293T cells were used to stimulate BMDCs for five 
minutes. Cell lysates were resolved on a 10% polyacrylamide gel and transferred to a 
nitrocellulose membrane for Western blotting. Upon development of blot with an anti- 
phosphotyrosine HRP antibody, both recombinant CCL20 and tissue culture supernatants 
from pcDNA3.1-CCL20 transfected cells, induced tyrosine phosphorylation within 
BMDCs. These bands were not evident in the media alone or mock transfected controls 
(Figure 5.2.11). This shows that CCL20 is inducing a signal cascade, and is biologically 
active. 
5.2.4 Verification of recombinant CCL20 expression in vivo. 
Recombinant CCL20 expression in vivo was confirmed by RT-CPR. In order to 
differentiate between recombinant and endogenous CCL20 mRNA, we utilised a 5' T7 
primer and a 3' CCL20 primer. The T7 promoter is 3' to the CMV promoter within the 
pcDNA3. I -CCL20 construct. Therefore, it is an integral part of the recombinant 
CCL20 
mRNA. However, it is not present within endogenous CCL20 mRNA. Recombinant 
CCL20 transcripts were only present in cDNA preps from pcDN3.1-CCL20 inoculated 
mice (Figure 5.2-12). Confirmation that these bands were not due to plasmid 
contamination was demonstrated by the absence of a band in the corresponding reverse 
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5.2.5 Recruitment of DCs following intranasal administration of PeDNA3.1-CCL20. 
After demonstration of the presence of recombinant CCL20 transcripts at the site of 
inoculation, it was critical to then demonstrate the functional activity of the recombinant 
CCL20. This was determined by flow cytometric analysis of DC number within 
inoculated versus naive NALT. Mice were inoculated with the plasmid encoding CCL20, 
via the intranasal route. At 48 and 72 hours NALT was harvested and DCs defined by 
CDI Ic, CDI lb and MHC class 11 expression (flow cytometry). The percentage of DCs 
was calculated as the proportion of the total cell number for each individual NALT 
(Figure 5.2.13). Each individual graph represents a separate experiment. At the 48 hour 
time point there is a trend towards increased DC number in pcDNA3. I -CCL20 inoculated 
NALT. However the difference between dosed and control mice was not significant and 
when the experiment was repeated with a larger group size, no such trend was observed. 
Due to the technical difficulties of harvest NALT, a large degree of variability can be 
seen, resulting in no significant difference between the vector control and the CCL20 
plasmid in any of the different experiments either at 72 or 48 hours. 
However, in a separate experiment NALT cells preps were pooled and analysed by flow 
cytometry as described previously. When the 48 hour pcDNA3.1-CCL20 group (n=5) 
were compared to the pooled vector control group (n=5), a2 fold increase in DC number 
can was observed (figure 5.2.14). This indicates that CCL20 expression increased DC 
number within pcDNA3. I -CCL20 dosed NALT. 
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5.2.6 Migration of MHC class 11+ cells upon subcutaneous administration of 
PcDNA3.1-CCL20. 
CCL20 has been reported to induce the migration of Langerhan cells to the skin (Dieu- 
Nosjean et al. 2000). By administration of CCL20 encoding plasmid subcutaneously, it 
was hypothesised that DC frequency should increase. This hypothesis was tested by the 
administration of 50ýtg of pcDNA3.1 -CCL20 or control vector, subcutaneously into the 
base of the tail. 24,36,48, and 72 hours later the tails were harvested and analysed for 
DC density by immunohistochernistry (MHC class 11+" cells). 
A typical section of tail tissue stained for MHC class 11 is illustrated in figure 5.2.15, 
NMC class 11+ cells are highlighted by arrows and were counted. At least three sections 
were taken per animal and from each section 5 field of views were blind counted. After 
24 hours and 36 hours, both CCL20 plasmid and vector control induced an increase in 
MEC class 11+" cells frequency. However, at 48 hours the pcDNA3. I -CCL20 dosed skin 
has higher DC numbers than the vector control, suggesting plasmid encoded CCL20 in 
situ is recruiting MHC class 11 positive cells. However, after 72 hours, the CCL20 dosed 
skin has a frequency of MEC class 11+ve cells equivalent to that found in the vector 
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5.2.7 Co-inoculation of pcDNA3.1-CCL20 with VR-SEAP. 
To examine the adjuvant effect of the plasmid encoded CCL20, pcDNA3.1-CCL20 was 
co-immunised with a plasmid encoding the reporter gene SEAP, VR-SEAP. 50ýtg of 
SEAP was co-inoculated with I 00[ig of pcDNA3.1 -CCL20 via the intranasal route. 
pcDNA3.1 or recombinant SEAP protein with cholera toxin (CT) were inoculated 
intranasally as controls. 5 mice were immunised per group, and each group were boosted 
on day 7 and day 14. On day 28, blood, vaginal fluid, NALT, CLN and spleens were 
harvested from each mouse and the antibody and T cell proliferation responses were 
examined. Mice inoculated with recombinant SEAP and CT demonstrated induction of 
IgG within the sera, IgA in vaginal washes and anti gen-speci fi cT cell proliferative 
responses in NALT and spleen (Figure 5.2.17 to 5.2.19). Plasmid DNA encoding SEAP, 
either alone or co-administered with plasmid DNA encoding CCL20 unexpectedly failed 
to demonstrate detectable serum IgG, vaginal IgA or T cell proliferative responses in 
spleen or NALT. Gel electrophoresis of VR-SEAP plasmid DNA indicated a high level 
of degradation that was not present in the initial investigation into the quality of the 
plasmid DNA. The degradation could explain the reason for the lack of immune 
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The biological properties of CCL20 suggested that this chemokine may be suitable for 
use as a genetic adjuvant. This was due to the observations that CCL20 was a potent 
chemoattractant for DCs, which are primary APCs capable of producing strong immune 
responses (Akbari et al. 1999). CCL20 was also shown to be upregulated within both 
epithelia (Dieu-Nosjean et al, 2000) and the mucosa (Power et al, 1997) after antigen 
challenge/infection. It was hypothesised that the over-expression of CCL20 at the site of 
immunisation would increase DC number at the site of immunisation and therefore 
increases the magnitude of the subsequent immune response. This may greatly enhance 
the efficacy of plasmid DNA vaccines. 
The intranasal route of immunisation has many advantages over parenteral routes; these 
include ease of administration, patient compliance and no requirement for injection. This 
route is more acceptable to patients and also shows greater efficacy than oral or rectal 
delivery in its capacity to generate combined mucosal and systemic immune responses 
(Klavinskis et al. 1999). Intranasal immunisation has also been shown to be capable of 
induction of cellular and humoral immunity (Gao et al. 1997). 
Studies within the respiratory tract have shown CCL20 is intrinsic to the recruitment of 
DCs to the trachea (Stumbles et al. 2001), and other mucosal compartments (Cook et al. 
2000). Here we have confirmed the expression of endogenous CCL20 and its cognate 
receptor CCR6 within NALT, supporting a biological role 
for CCL20 in the recruitment 
of CCR6 positive cells to NALT. 
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CCL20 was cloned into an expression plasmid and production of the encoded protein 
confirmed by in vitro translation and western blot analysis. Although anti-murine CCL20 
was not available, we have shown that anti-rat CCL20 cross-reacts with murine CCL20 
(5.2.5). We were therefore able to use anti-rat CCL20 to prove expression of plasmid 
encoded murine CCL20. We then attempted to confirm the biological activity of the 
plasmid encoded CCL20 by calcium flux, transmigration assay and intracellular 
signalling (tyrosine phosphorylation). 
It has been reported that CCL20 can induce calcium flux within CCR6 positive cells 
(Baba et al. 1997). Therefore to validate the biological activity of the plasmid encoded 
CCL20 we investigated its potential to induce calcium flux in rat splenocytes. We 
compared the capacity of tissue culture supernatants from pcDNA3.1-CCL20 or control 
transfected HEK293T cells to induce calcium flux with that of recombinant CCL20 (rat) 
and SDF- I a, which have been shown to induce calcium flux (Delgado et al. 1998). Due 
to the lack of murine CCL20 at this time, the experiment had to be performed with rat 
splenocytes as recombinant rat CCL20 was available. It was theorised that the rat 
splenocytes would express CCR6, as mRNA for CCR6 has previously been identified 
within murine spleen (Varona et al. 1998). Also, no antisera to rat CCR6 was available at 
this time. Therefore, we could not confirm the presence of CCR6 protein on these cells. 
Although a calcium flux was not induced by either recombinant or plasmid encoded 
CCL20, the positive control, SDF-la, also failed to induce calcium flux. However, a 
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calcium flux could be induced by the detergent Triton. The simplest explanation to the 
failure of this experiment was that the cells were non-viable at the time of this analysis. 
However, it may also due to our inability to ensure the cells within a field of view were 
cells CCR6+", due to a lack of available anti-CCR6 antibody at the time of the 
experiment. To examine if CCL20 could induce a calcium flux in human or murine 
CCR6+" stable cell-lines, these cells were stimulated with the appropriate species of 
CCL20. Although a calcium flux could be observed uPon addition of human CCL20, the 
magnitude of the response was not significantly above background to be defined as a 
positive. 
Another biological property of CCL20 is to induce CCR6+" cell migration in a 
concentration dependant manner (Dieu et al. 1998; Charbonnier et al. 1999; Yang et al. 
1999; Dieu-Nosjean et al. 2000). Also, bone marrow derived cells have been shown to 
migrate to CCL20 (Biragyn et al. 2001). Therefore, the capacity of recombinant and 
plasmid encoded CCL20 to attract DCs was assessed. Murine bone marrow derived DCs 
were cultured in the presence of GM-CSF and their CCR6 status was confirmed by flow 
cytometry (figure 5.2.10). However, we failed to show an increase in migration under any 
of the conditions tested. A detailed study of the literature revealed that studies migration 
of CCR6+ve cells in response to CCL20 utilised human CCL20, no such effect was 
shown with murine CCL20 (Ogata et al. 1999). Our data support these observations. 
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CCR6 is a G-protein coupled receptor (Zaballos et al. 1996; Baba et al. 1997), interaction 
of these receptors with their cognate ligands results in signalling via the Map kinase 
pathway (Chuang and Ng 1994; Hirano et al. 1996) and requires tyrosine 
phosphorylation. Therefore, to confirm the biological activity of our CCL20 we 
examined the capacity of plasmid encoded CCL20 versus recombinant CCL20 to induce 
tyrosine phosphorylation in CCR6 positive cells. Bone marrow derived DCs incubated 
with either recombinant or plasmid encoded CCL20 exhibited increased levels of tyrosine 
phosphorylation in comparison to control cultures (Figure 5.2.11). This confirmed the 
capacity of plasmid encoded CCL20 to signal in a biologically significant manner. 
In order to confirm that it is possible to express a plasmid DNA encoded transgene by 
intranasal inoculation, we examined levels of plasmid encoded CCL20 message by 
RT-PCR. pcDNA3. I -CCL20 dosed NALT showed CCL20 message levels above those of 
pcDNA3.1 dosed NALT and normal controls. The validity of this observation was 
confirmed by the lack of signal in the none reverse transcribed samples. Therefore, it is 
likely that this message is transcribed and the local levels of CCL20 are elevated. As we 
have already shown that the expressed CCL20 is biologically active, it is likely that this 
will result in an increase in the influx of DCs. 
To test the hypothesis that local over-expression of CCL20 will increase the efficiency of 
recruitment of DCs in vivo, plasmid DNA encoding CCL20 was 
inoculated via the 
intranasal route into balb/c mice. NALT DCs were identified on the basis of CD 
IIc and 
NIHC class 11 expression. Recruitment of DCs due to recombinant 
CCL20 expression was 
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compared to recruitment to empty plasmid DNA. Initial results were inconclusive, xN, -ith 
no significant difference between empty plasmid and plasmid encoded CCL20 (Figure 
5.2.13). NALT is a very difficult environment to work on in murine systems. Efficient 
recovery of the complete NALT compartment is troublesome, due to the difficult-v, of 
isolating cells from this bony environment. It is likely that this variability cell harvesting 
obscured any observable biological trend. Also, the number of DCs within NALT, as a 
proportion of total cells, is very small (less than 1%) making statistically valid cell 
numbers difficult to obtain from a single mouse. Therefore, we repeated the experiment 
with pooled NALTs from 5 mice. From the pooled samples we were able to determine a 
50% increase in DC number within pcDNA3. I -CCL20 dosed NALT. We also confirmed 
this observation of increased DC number by immunohistochemical analysis of skin dosed 
subcutaneously with either pcDNA3.1 -CCL20 or empty pcDNA3.1. Slides were bi inded, 
and three independent fields of view counted per section, with 3 sections in total. At 24 
hours there is a greater number of MHC class 11 cells were counted, this is possibly due to 
the mechanical damage of the injection, resulting in an increased recruitment of DCs 
(p=0.30). At 36 hours, CCL20 encoded plasmid and the empty vector were equivalent 
(p=0.13). The lack of significant difference at 36 hours between control and dosed skin is 
likely to be due to the lag in recombinant CCL20 production and the time required for the 
recruitment of significant DC numbers. An increase can be observed between control and 
CCL20 encoded plasmid dosed skin at 48 hours, suggesting that the transgene 
is being 
expressed and NMC class 11 cells are being recruited (p=0.01). There was no significant 
difference in recruitment at 72 hours between the CCL20 encoding plasmid and the 
empty vector plasmid (p=0.53). The recruitment of DCs to the skin 
by CCL20 is well 
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documented (Charbonnier et al. 1999; Dieu-Nosjean et al. 2000; Nakayama et al. 2001). 
and is further evidence to support the biological activity of our plasmid encoded CCL20. 
The lack of significant difference between control and recombinant plasmid encoded 
CCL20 dosed skin at the 72-hour time point could be explained by a number of factors. It 
is possible that there was a CpG mediated immune response against plasmid transfected 
cells, and therefore a dramatic fall in the local levels of recombinant CCL20 due to their 
elimination. This would allow any DCs present to migrate to draining lymph nodes by 
their default migratory pathways (CCR7 and CCL2 1). Alternatively, the DCs at this point 
may have reached a stage of maturity when they naturally down regulate CCR6, 
concomitantly up-regulating CCR7 inducing migration to draining lymph nodes. 
However, we expect the initial priming events to have occurred before 72 hours and 
migration from the site of immunisation to the draining lymph node is required to prime 
naYve T cells. Therefore, these observations suggest that increased DC number migrate to 
the draining lymph node and may lead to heightened immune response. 
With evidence that the CCL20 expressed by the plasmid elicited biological activity in 
vivo, a study was undertaken to examine the efficiency of CCL20 in enhancing the 
response to the target antigen secreted alkaline phosphatase (SEAP). After the secondary 
boost, both humoral and cellular responses were measured. In the experimental groups 
using plasmid encoding SEAP either with or without CCL20, there was no detectable 
antibodies production or T-cell proliferation. However, in the positive control, of 
173 
recombinant SEAP administered with the adjuvant cholera toxin, both antibodies and T- 
cell proliferation could be detected. The plasmid conformed to the initial requirements of 
having a purity of 1.8 as determined by the absorbance at 260nm versus 280nm, and it 
also transfected the cells at equivalent commercially derived plasmid preparations. 
However, when the plasmid was re-examined after the course of immunisations, by gel 
electrophoresis, the plasmid was degraded. In vitro transfections resulted in levels SEAP 
production 2 logs lower than with a new preparation of SEAP vector. This suggests there 
was a problem within the plasmid preparation, and that if time permitted a future attempt 
would give a definitive answer as to the effect of CCL20. 
A possible explanation for the absence of an adjuvant effect observed by CCL20 in this 
study is the recent report that CCL20 may play a role in retaining CCR6 expressing cells 
in the tissue that have been previously recruited by another chemokine MCP- 
4(macrophage chemotactic protein-4) of CCR2 positive cells (Vanbervliet et al. 2002). 
This gives rise to the potential of two opposing hypothesis, is there a threshold effect, 
where upon above a certain level of CCL20, CCR6 positive cells are recruited. Or is there 
an additive effect, where upon the greater the concentration of CCL20 the more CCR6 
positive cells are recruited. If the first hypothesis is true, then the use of CCL20 as a 
genetic adjuvant would be limited once the threshold has been reached, however, if the 
second hypothesis was true, then the adjuvanticity of CCL20 could conceivably be very 
powerful, and dependant upon the transfection efficiency of the plasmid. 
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Here we have produced biologically active recombinant CCL20 and shown that plasmid 
encoded CCL20 is expressed at the site of administration. This resulted in increased DC 
influx. However, it was not possible to show an enhanced immune response as a result of 
increased local DC number, which may have been due to problems with the immunogen 
encoding vector as discussed. It is likely if these experiments were repeated a significant 
difference would be found. 
With both recombinant murine CCL20 and monoclonal antibodies to CCR6 now 
commercially available, investigation of murine chemotactic responses would be much 
easier. Investigating if CCL20 retains cells or induces active migration would be 
important to ascertain. Examining the adjuvanticity to a plasmid encoded antigen is 
essential, however, possibly the co-immunisation with a MCP-4 encoded plasmid might 
induce a broader spectrum response. 
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Chapter 6- Discussion and Future Studies 
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6.1 Discussion 
Plasmid DNA expression vectors have many attributes that make it an ideal candidate as 
a vaccine vector. Plasmid DNA is easy to manufacture and manipulate, and has been 
shown to induce not only cellular, but also humoral immunity. Many routes of 
immunisation have been investigated to deliver plasmid DNA, including intramuscular 
(Danko and Wolff 1994; Yang et aL 1995), intravenous (Wu and Wu 1988; Kawabata et 
al. 1995), subcutaneous (McCluskie et al. 1999), intranasal (Wheeler et al. 1996; Gao et 
al. 1997) and intradermal (Rakhmilevich et al. 1996; Choi et al. 1997; Degano et al. 
1998) to the less patient compliant route of targeting plasmid DNA to lymph nodes 
(Lehner et al. 1996; Lu et al. 1998). The main disadvantages of plasmid DNA vaccines 
are the amount of DNA necessary to elicit protective immune responses in man, and the 
degradation of the DNA depending upon the route of immunisation. 
The hypothesis of this thesis is that the by increasing the delivery of plasmid DNA both 
to mitotic and non-mitotic cells, or by increasing the number of APCs presenting the 
target antigen, the immunogenicity of plasmid DNA vaccines can be increased. Chapter 3 
discussed the application of cationic lipids in facilitating and improving binding and 
uptake of plasmid DNA into cells and protection of plasmid DNA from degradation. 
Chapter 4 examined a novel peptide that could act in a similar manner to cationic lipids, 
but could cross the cell membrane via a non-endocytic mechanism, and chapter 5 
discussed the role of a new potential molecular adjuvant, to increase the efficacy of the 
immune response, and thus potentially reduce the amount of plasmid DNA required. 
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Within plasmid DNA vaccine development, the route of immunisation is an essential 
consideration. An ideal goal for future vaccine administration would include a needle 
free, inexpensive method of vaccine delivery targeting a mucosal surface, the primary site 
of transmission for many pathogens. The mucosal surfaces include the nasopharynx, 
vagina, rectum, and gastrointestinal tract. In each of these environments, degradation of 
naked plasmid DNA has been reported after a few minutes, with a significant reduction in 
transgene expression (Nomura et al. 1997). Delivery of plasmid DNA by the intranasal 
route has been shown to induce both a mucosal and a systemic response (Kuklin et al. 
1997; Asakura et al. 1999; Klavinskis et al. 1999), with the generation of both Th, and 
Th2responses (Kanellos et aL 2000; Debin et aL 2002; Tanaka et al. 2002), which makes 
this an optimal route for mucosal immunisation. 
There are several methods of protecting plasmid DNA from endonuclease degradation for 
optimal efficiency of gene expression. We have shown that complexing plasmid DNA 
with cationic lipids, can be an effective way of increasing the efficiency of transfection. 
However, the cationic lipids are preferentially targeted to the endosome and require aid in 
escaping to the cytosol (Nakanishi and Noguchi 200 1). The majority of plasmid DNA can 
be found in the endosome after cationic lipid mediated transfection. There is a constant 
loss of plasmid DNA at each cellular barrier, including cell entry, escape from the 
endosome and nuclear entry (Zuhom and Hoekstra 2002). Identifying non-viral 
mechanisms that overcome these cellular barriers is of critical importance. The chemical 
composition of the cytofectins and the formulation of the plasmid DNA with the cationic 
lipid can attribute to the variances observed in the transfection efficiency (Thierry et al. 
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1997; Ferrari et al. 2002). We have examined a range of variables, examining the relative 
amount of lipid complexed with plasmid DNA to determine the most efficient ratio for 
transfection, and rationally designing a protocol for intranasal immunisation. 
In NALT, DCs are interspersed among the epithelial lining of the nasopharynx. We have 
shown that following transfection with a GFP expressing plasmid that the transgene can 
be observed in sections of NALT tissue, and that the plasmid DNA is preferentially taken 
up by the mucososecretory glands. When cells from NALT and its draining lymph nodes, 
the CLN, are purified by flow cytometry into DC's and T and B cells, the transgene was 
observed within the DCs but not within the lymphoid subsets. DCs are a prime target for 
any potential vaccine candidate, as direct transfection of DCs will result in transgene 
expression and antigen displayed on both MHC class I and class 11, broadening the depth 
of the response. It is still currently unclear whether plasmid DNA directly transfects DCs, 
or whether DCs are cross-primed from other cells, for example epithelial cells, that 
contain the transgene. In support of our study, antigen and reporter genes have been 
demonstrated in macrophages, Langerhan' cells and DCs present both at the site of DNA 
vaccine delivery and in draining lymph nodes (Chattergoon et aL 1998; Akbari et aL 
1999; Barnfield et al. 2000). This suggests that APCs are transfected in situ and migrate 
to draining lymph nodes or alternatively are transfected within lymph nodes following 
lymphatic drainage of plasmid DNA (Bamfield et al. 2000). Conclusively, data has 
demonstrated plasmid encoded mRNA in isolated DCs following either intradermal or 
mucosal vaccine delivery (Bouloc et al. 1999; Barnfield et al. 2000). Interestingly, direct 
transfection of DCs has been extremely difficult to demonstrate with plasmid DNA in 
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vitro (Denis-Mize et al. 2000), suggesting instead that in vivo the transgene is present due 
to cross-priming. However, it should be noted that bone marrow derived DCs, although 
displaying many characteristics similar to DCs within the mucosa, are generated in the 
presence of cytokines that are rather not present, or at different concentrations, than those 
expressed in vivo. Studying DCs ex vivo is also problematic since physical removal of 
DCs from connective tissue can also alter their properties, and induce maturation. Thus 
although in vitro manipulation of DCs is a powerful tool, it cannot replicate an in vivo 
environment. It is well established that DCs phagocytose apoptotic cells (Albert et al. 
1998; Rovere et al. 1998; Van Zanten et al. 2002), thus considering that cationic lipids 
have been reported to be toxic (Dass 2002), it is possible that transfected cells, undergo 
apoptosis and expressed plasmid DNA encoded protein is taken up by the DC. 
DCs are highly phagocytic, and all phagocytosed material is rapidly degraded within the 
endosome. Thus a novel delivery system that can bypass the endosome has great potential 
for transfecting DCs- Peptides from the proteins Antennapedia, HIV-Tat and VP20 from 
HSV have all been reported to translocate across the cellular membrane in an endosome 
independent manner (Morris et al. 2001). Primarily these peptides have been investigated 
for their potential to co-translocate a fused peptide, for efficient delivery into the cytosol. 
We have shown that a peptide containing the translocation domain of the Antennapedia 
peptide, fused to a peptide consisting of 16 lysines via a3 glycine 
hinge, can transport 
DNA across the membrane, and expression of the plasmid encoded transgene can 
be 
observed within cell lines. However, the transfection efficiency could not 
be replicated 
when a new batch of peptide from the same manufacturer was used. 
This could be due to 
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a number of reasons, storage of the peptide is critical, trace contaminations within the 
peptide can affect transfection, formulation of the peptide (pH or salinity) is critical. 
One of the main disadvantages of plasmid DNA is the necessity for large doses of DNA 
to facilitate the generation of an immune response in man. There have been many studies 
studying the effects of co-immunising chemokines, cytokines and growth factors with a 
plasmid encoded target antigen in the attempt to reduce the quantity of plasmid DNA 
required to induce a response (Okada et al. 1997; Xin et al. 1999; Ou-Yang et al. 2002; 
Luo et al. 2003). The most successful strategies within the literature involve the 
recruitment of DCs to the site of immunisation, and an increase in the amount of 
inflammation induced by the plasmid (Lu et al. 1999). The identification of CCL20, a 
chemokine that was reported to specifically attract immature DCs, suggested this 
chemokines as a prime candidate to enhance the immunogenicity of mucosally 
administered plasmid DNA vaccines (Hieshima et aL 1997). We cloned CCL20 into an 
expression vector and studied the biological activities of this chemokine on a variety of 
cell lines and primary cells. Preliminary data from this thesis suggested that CCL20 does 
not induce migration in a transmigration assay, or stimulate a calcium flux in the cells 
tested. Within the literature, there is a divergence between humans and mice in the 
recruitment of CCR6 expressing cells (especially CD34+ haemopoetic precursor cells 
cultured in GM-CSF) to CCL20. Fushimi et al, 2000, reported that supernatants of cells 
infected with a vaccinia virus (VV) encoding CCL20 were chemotactic for bone marrow 
derived DCs. They also reported that intraturnoral immunisation with VV encoding 
CCL20 induced an accumulation of DCs in vivo. Biragyn et al, 2001 also reported the 
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role of CCL20 and the P-defensins in binding to CCR6 and attracting bone marrow 
derived DCs. Iwasaki and Kelsall, 2000, isolated DCs from within the subepithelial dome 
of the Peyer's patches and showed transmigration of these cells in response to CCL20. 
However, in another study, transmigration of DCs to murine CCL20 could not be 
observed (Ogata et al. 1999). We have studied the transmigration of murine bone marrow 
derived DCs with both commercially produced recombinant murine CCL20 and 
supernatants cell lines transfected with an expression plasmid encoding murine CCI-20, 
without any migration being observed. There are reports that depending upon the 
cytokine environment within the bone marrow derived culture, different phenotypes and 
characteristics of the resulting DCs can be generated. Analysis of the phenotype of the 
DCs, for the cultures generated in this study, indicated expression of CCR6, the receptor 
for CCL20. It is possible that murine CCL20 does not induce migration since Iwasaki and 
Kelsall, 2000, Birygan et al, 2001 and Fushimi et al, 2000, used human CCL20 in their 
studies to demonstrate recruitment. The data for this thesis complement the observation 
of Ogata et al, 19999, which were unable to detect significant migration of murine DC by 
murine CCL20. 
It has recently been proposed that CCL20 works in combination with CCL13 to induce 
transmigration in vivo. A sequential triggering of chemokine receptors has been reported 
to induce migration of DCs from the blood to the site of infection. Vanbervliet et al, 
2002, suggest that CD 14 + precursor monocytes initially migrate to CCL13, a CCR2 
binding chemokine, and then migrate along a gradient to CCL20. Both chemokines have 
been observed to produce complimentary gradients, with CCL13 expressed in basal 
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epithelial cells at the contact of blood vessels, while CCL20 expression is restricted to 
epithelial cells bordering the external milieu. The migration of blood monocytes through 
the tissue in response to CCL13 may mature and upregulate surface expression of CCR6 
and thus induce responsiveness to a CCL20 gradient. 
This thesis demonstrated that expression of plasmid DNA encoded proteins could be 
enhanced by incorporation of cationic lipids or novel peptides. It has also demonstrated 
that a plasmid encoding CCL20 induces recruitment of DCs in vivo, thus potentially 
enhancing the immune response when co-administrated with a plasmid encoding an 
antigen. These modifications to vaccine design may incrementally facilitate the 
translation of this vaccine technology to the clinic. 
The present study undertook to enhance the efficiency of plasmid DNA delivery in vivo 
by complexing the DNA with cytofectins or with peptides. A further aim was to enhance 
the immunogenicity of plasmid DNA by recruiting DCs at the site of immunisation. We 
have shown that optimisation of the molar ratio of plasmid DNA to cytofectins can 
enhance the production of the transgene both in vitro and in vivo, and that the transgene 
can be expressed in DCs at the site of inoculation and at the draining lymph node. 
We 
have also shown that transfection can be achieved using an Antennapedia peptide 
delivery system, however further investigation is necessary to elucidate 
if this peptide 
facilitates plasmid DNA uptake in an endosomal independent manner. 
Finally we have 
shown that the chemokine CCL20 can attract 
DCs in vivo, and although the adjuvant 
effect of this chemokine in augmenting 
immunogenicity of an antigen encoded plasmid 
was undertaken, the results were inconclusive, and need 
to be reassessed. 
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A recent observation suggested that blood DCs are recruited through a sequential 
activation of the chemokines receptors CCR2 and CCR6 (VanbervIiet et al. 2002). This 
suggests that administration of a plasmid that encodes CCL13 and CCL20 using an 
internal ribosome entry site (IRES) could increase the recruitment of DCs to the site of 
immunisation. Ligation of CCR2 by CCL13 has been shown to induce migration of DCs 
(de la Rosa et al. 2003; Liu et al. 2003). Although CCL13 has not been used as a 
molecular adjuvant, there is evidence to indicate that another CCR2 ligand, CCL2 
enhanced the immunogenicity of a DNA vaccine (Eo et al. 2001). Co-immunisation with 
plasmid DNA encoding gB of herpes simplex virus and CCL2 enhanced the immune 
response to the target antigen, which was skewed to a Th2 response inducted by the 
immunoglobulin isotypes and IL-4 expression produced by CD4 T cells (Eo et al. 2001). 
If complementary gradients of CCL13 and CCL20 are established in vivo as reported by 
Vanbervliet et al, 2001 then an increase in the recruitment of DCs should be achieved by 
the dual plasmid encoded expression of both CCL13 and CCL20. 
Chemokines expressed as a fusion protein with an antigen may have the potential to 
improve the immunogenicity of the cognate antigen. Immunisation with plasmid DNA 
encoding a fusion protein of and a target antigen has been reported to not only facilitate 
the uptake of the fusion protein to DCs via CCR6, but also to induce migration of 
immature DCs (Biragyn et al. 2001). Using the same rationale, plasmid DNA encoding 
the 16 amino acid Antennapedia peptide in tandem with a target antigen could be 
constructed. Recently a fusion protein containing the ovalbumin SIINFEKL 
CTL peptide 
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was shown to induce a strong CTL response (Pietersz et al. 2001). This suggests that 
CTL epitopes can be transfected directly into the cytosol and gain access to neýN ly 
synthesised MHC class I molecules. Based on this premise, direct transfection of DC 
could be bypassed by transfecting stromal cells with plasmid DNA encoding a secreted 
fusion protein encoding Antennapedia and the target antigen for delivery to the DC. 
Recent studies have indicated that expansion of DC subsets administration of growth 
factors, for example GM-CSF orfms-like tyrosine kinase ligand (Flt3L), can increase the 
immunogenicity of a co-administered target antigen. Flt3L, a growth factor for early 
haematopoietic progenitor cells (Lyman et aL 1993) has been reported to induce the 
expansion of DCs (Maraskovsky et aL 1996). and generate a strongly polarise Thl 
response (Morelli et al. 2000). Co-administration of plasmid DNA encoding HBV core 
antigen and Flt3L showed that the Flt3L suppressed humoral responses to the target 
antigen (Kwon and Park 2002). Another study showed that inoculation with plasmid 
DNA encoding Flt3L, increased the number of DCs at both the site of immunisation and 
the draining lymph node (Sang et aL 2003). 
CD40L, a member of the TNF gene family that is expressed on T cells upon Ag 
recognition may represent another genetic adjuvant. CD40L is upregulated following 
TCR ligation and induces co-stimulatory activity on DCs via engagement of CD40, 
which provides a second co-stimulatory signal for full activation of T cells. (Grewal and 
Flavell. 1998). Plasmid DNA encoding CD40 DNA was found to enhance cellular 
immune responses such as induction of IFN-7 and CTL activity when mice were 
185 
vaccinated with plasmid DNA encoding P-galactosidase (Gurunathan et al. 1998). 
Furthermore, co-immunisation with plasmid DNA encoding CD40L with the F and G 
proteins from Rous Sarcoma Virus (RSV) has been reported to enhance Thl (IL-2 and 
IFN-7) cytokine responses to the co-inoculated antigens, increase the expression of 
TNF-cc and Nitric Oxide, increase the humoral response to the target antigens and 
accelerate virus clearance (Tripp et al. 2000). 
In conclusion, plasmid DNA has a great potential as a vaccine vector, with its ease of 
manufacture and manipulation. Continual advances in elucidating the mechanisms of 
regulating the immune response, is revealing new and novel molecular adjuvants. Using 
chemokines, growth factors or co-stimulatory molecules, immune responses can be 
augmented and the amount of plasmid DNA required to induce protection against 
infection disease in man may be reduced. 
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6.2 Future Studies 
The aims of the strategies discussed within this thesis focus on improving the immune 
response generated towards a target antigen, with the ultimate aim of improving the 
efficacy of plasmid DNA vaccination. Examining the CTL and antibody responses 
generated by the vaccine alone or combined with CCL20, Antennapedia or lipid 
formulation can identify the immunogenicity of the strategy. However, the true test of the 
effectiveness of these candidates listed within is to apply these approaches to prevent 
disease or viral clearance upon pathogen challenge. The principle behind the approach 
was for a simple, effective mucosal vaccine that can be given via the intranasal route, 
thus negating the necessity for a needle based delivery system. Therefore, a model system 
that is clearly defined and targets the mucosa would be appropriate for showing the 
efficacy of these approaches. One such challenge system is the use of influenza virus. 
Influenza is normally cleared from the lungs within 10 days post infection, with viral 
RNA sequences undetectable in the lung by day 14, within the O-NALT within 12 days, 
and within the D-NALT within 17 days (Liang et al. 200 1). By examining antibody titres, 
CTL responses, and viral clearance rates, one can ascertain the increased effectiveness of 
these modified vaccine strategies, and that by their addition one can reduce the amount of 
plasmid DNA required to induce an immune response. 
Another mucosal viral challenge system is by Herpes 
Simplex Virus. One of the key 
attributes of a mucosal vaccine 
is the induction of mucosal responses at distal sites. 
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Immune responses generated by plasmid DNA encoding HSV glycoprotein B delivered 
intranasally have been observed to include interferon-producing T and NK cells and the 
IgG2a isotype immunoglobulin. With co-immunisation of cytokine encoded DNA (IL-12 
or IL- 18) have shown enhanced resistance to lethal vaginal HSV infection, however the 
response was never as high as that observed with UV-inactivated HSV . By using the 
methods investigated within the thesis, the immune response towards the plasmid DNA 




COMMONLY USED BUFFERS AND PROCEDURES 
All chemicals were of analytical grade and all solutions were made in 
glass with double distilled water. 
1.1 STANDARD BUFFERS AND REAGENTS 
(1). Phosphate Buffered Saline (pH 7.4): 
Sodium Chloride 100MM 
Potassium Chloride 2.7mM 
Na2HP04 80mM 
NaH2PO4 20mM 
pH to 7.4 
(2). Tris Buffered Saline (pH 7.0): 
Tris base 20mM 
Sodium Chloride 137mM 
PH to 7.0 
(3). EDTA (0.5M pH 8-0): 
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Disodium EDTA 0.5M 
(4). STE: 
NaCl 0.1m 
Tris Cl (pH 8.0) 1 omm 
EDTA (pH 8.0) 1mm 
(5). TE: 
Tris Cl (pH 8.0) lomm 
EDTA (pH 8.0) 1mm 
(6). Plasmid DNA Maxi Preparation Solutions 
Solution 1 
Glucose 50mM 
Tris-CI (pH 8.0) 25mM 
EDTA (pH 8.0) lomm 
Lysozyme 1 mg/mI 
Solution 2 
Sodium Hydroxide 0.2M 
SDS 1% 
Solution 3 
potassium acetate 5M 60 ml 
glacial acetic acid 11.5 ml 
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ddH20 28.5 ml 
Total Volume: 100 ml 
Filter sterilize. The resulting solution: 3M potassium, 5M acetate and is pH 4.8. 
(7). TBE Buffer: 
Tris borate 0.089M 
Boric acid 0.089M 
EDTA (pH 8.0) 0.002M 
(8). TAE Buffer: 
For 1 litre of 50x stock solution: 
Tris base 242g 
Glacial acetic acid 57.1 ml 
EDTA (pH 8.0) 0.5M 100ml 
Final working solution: Tris acetate 0.04M, EDTA 0.001 M 
(9). SIDS Acrylamide Gel 
(A). 10% Separating Gel: 
40% Acrylogel (BDH, Poole, U. K) 








10% APS 60 pl 
TEMED 7pl 
Final volume 10 ml 
(B). Stacking Gel: 
40% Acrylogel (BDH, Poole, U-K) 0.5ml 
0.5M Tris PH 6.8 1.25 ml 
10% SIDS 50 pi 
Water 3.5 ml 
10% APS 35 pl 
TEMED 4pl 
Final volume 5 ml 
(10). Reducing Sample Buffer for SDS Page Analysis: 
Tris Cl pH 6.8 0.1 25M 
10% SIDS 0.14M 
Glycerol 20% v/v 
2-mercaptoethanol 2% v/v 
Bromophenol Blue 0.2mM 
Deionised water 0.03M 





Dissolved in 1 litre distilled water. Stored at 40C; 300 ml 
5x stock diluted with 1.2 litre distilled water. 
(12). Western Blot Transfer Buffer 
Glycine 0.192 M 
TRIS base 25 mM 
Methanol 20% 
(13). Terrific Broth: 
Bactotrytone 12g 
Bacto-yeast extract 24g 
Glycerol 4 ml 
Make in 900 ml and after autoclaving add 100 ml of 0.17M KH2PO4,0.72M 
K2HP04. 













(15). RPMI+ or DMEM 
Penecillin 10ou/ml 
Streptomycin 1 oopg/ml 
L-Glutamine 2mM 
Fetal Calf Serum (Heat Inactivated) 10% 
In RPMI-1640 or DMEM. 
(16). Hearnatoxylin Counter Stain 
1 litre of solutions A and B are mixed with 20ml solution C. 
Solution A: - 
10% aluminium ammonium sulphate solution 
Solution B: - 
10% Chloral Hydrate 
0.5% Citric Acid 
0.1% Sodium iodate 
Solution C: - 
10% Haernatoxylin in 100% Ethanol 
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1.2 MEASUREMENT OF pH 
pH was measured using PHM standard pH meter (Radiometer) with a 
combination gel epoxy electrode (Whatman, ). Measurement was accurate to ± 
0.05 pH units. 
1.3. AUTOCLAVING 
All buffers solutions used in cell studies were autoclaved at 15 pounds per 
square (psi) inch for 30 minutes / 500 ml in an Express RG2 portable autoclave 
(Arnold and Sons, UX). 
Plastic tips for micropipettes for culture studies were autoclaved at 15 psi 
for 15 minutes in an Autoclave-SUA (British Steriliser Co, U. K). 
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Appendix 2 
SOURCES OF REAGENTS 
2.1. CHEMICALS 
Acetic acid - BDH, Poole, U. K. 
Bovine Serum Albumin - Sigma, Poole, U. K. 
Bromophenol blue - BDH, Poole, U. K. 
Commassie brilliant blue - Sigma, Poole, U. K. 
Disodium clihydrogen orthophosphate - BDH, Poole, U. K. 
EDTA (ethyl enediaminetetrac etic acid) - BDH, Poole, U. K. 
Ethanol (absolute) - BDH, Poole, U. K 
Ethicliurn Bromide - BDH, Poole, U. K. 
Glucose - BDH, Poole, U. K. 
Glycerol - BDH, Poole, U. K. 
Glycine - BDH, Poole, U. K. 
Glutaralderhyde - BDH, Poole, U. K. 
Hydrochloric acid (concentrated) - BDH, Poole, U. K. 
Hydrogen Peroxide (30% w/v) - BDH, Poole, U. K. 
LiCl (lithium chloride) - BDH, Poole, U. K. 
Low EEQ low melting point (LMP) agarose - Sigma, Poole, U. K. 
Methanol - BDH, Poole, U. K. 
2-p-mercaptoethanol (2-NEE) - BDH, Poole, U. K. 
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N-N-Dimethlyformamide - Sigma, Poole, U. K. 
Nonident P40 (NP40) - BDH, Poole, U. K. 
O-phenylenediamine Dihydrochloride - Sigma, Poole, U. K 
Paraformalderhyde - Sigma, Poole, U. K. 
Potassium acetate - BDH, Poole, U. K. 
Sodium azide - BDH, Poole, U. K. 
Sodium chloride - BDH, Poole, U. K. 
Sodium clihydrogen orthophosphate - BDH, Poole, U. K. 
Sodium dodecyl sulphate (SDS) - BDH, Poole, U. K. 
Sodium hydroxide - BDH, Poole, U. K. 
Tris (hydroxymethyl) methylamine (Tris) - BDH, Poole, U. K, 
Triton X- 100 - BDH, Poole, U. K. 
Tween-20 - BDH, Poole, U. K. 
2.2. ENZYMES, ENZYME INHIBITORS (INCLUDING PROTEINS), MITOGENS 
Brefeldin-A - Sigma, Poole, U. K. 
Deoxyribonuclease-I - Sigma, Poole, U. K. 
Levaimisole - Sigma, Poole, U. K. 
Lysozyme - Sigma, Poole, U. K. 
Monensin - Sigma, Poole, U. K. 
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2.3. CULTURE PRODUCTS 
DMEM - Gibco BRL, Paisley, U. K. 
Fetal Calf Serum - PAA Laboratories, Cambridge, U. K. 
L-Glutamine - Gibco BRL, Paisley, U. K. 
RPMI-1640 - Sigma, Poole, U. K. 
Penicllin - Gibco BRL, Paisley, U. K. 
Streptomycin - Gibco BRL, Paisley, U. K. 
2.4. CHEMOKfNES 
CCL20 - Peprotech, London, U. K. 
CCL20 - R&D Systems, Abingdon, U. K. 
GM-CSF - Peprotech, London, U. K. 
GM-CSF - R&D Systems, Abingdon, U. K. 
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